• acne vulgaris;
  • aryl hydrocarbon receptor;
  • aryl hydrocarbon receptor nuclear translocator;
  • c-Myc;
  • hair follicle;
  • sebaceous gland;
  • stem cells;
  • 2,3,7,8-tetrachlorodibenzo-p-dioxin


  1. Top of page
  2. Abstract
  3. Introduction
  4. Chloracne – an environmental disease
  5. Dioxin – the most potent environmental chloracnegen
  6. Mechanisms of chloracne
  7. Conclusion
  8. References

Abstract:  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is among the most toxic pollutants known to date that serves as a prototype for a group of halogenated hydrocarbon compounds characterized by extraordinary environmental persistence and unique ability to concentrate in animal and human tissues. TCDD can elicit a complex array of pleiotropic adverse effects in humans, although chloracne, a specific type of acne-like skin disease, is the only consistent manifestation of dioxin intoxication, thus representing a ‘hallmark’ of TCDD exposure. Chloracne is considered to be one of the most specific and sensitive biomarkers of TCDD intoxication that allows clinical and epidemiological evaluation of exposure level at threshold doses. The specific cellular and molecular mechanisms involved in pathogenesis of chloracne are still unknown. In this review, we summarize the available clinical data on chloracne and recent progress in understanding the role of the dioxin-dependent pathway in the control of gene transcription and discuss molecular and cellular events potentially involved in chloracne pathogenesis. We propose that the dioxin-induced activation of skin stem cells and a shift in differentiation commitment of their progeny may represent a major mechanism of chloracne development.


hair follicle


sebaceous gland




  1. Top of page
  2. Abstract
  3. Introduction
  4. Chloracne – an environmental disease
  5. Dioxin – the most potent environmental chloracnegen
  6. Mechanisms of chloracne
  7. Conclusion
  8. References

Technological progress has created great benefits for humanity, but all too often has come at the price of escalating health hazards arising from unwanted industrial by-products and chemical waste. The impact of environmental pollution on human health is a novel and formidable evolutionary challenge. Thus, understanding the molecular, cellular, clinical and epidemiological aspects of exposure to environmental pollutants is essential for our future survival.

Perhaps the most vivid example of toxic chemical agents is the halogenated hydrocarbon 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) that serves as the prototype for a large group of polyhalogenated dibenzo-para-dioxins which evoke a wide range of adverse toxic effects in humans and animals. In these tricyclic aromatic compounds, hydrogen atoms can be substituted by up to eight chlorines, thus permitting about 75 different dioxin isomers. Among them, TCDD with four chlorine atoms in lateral positions (Fig. 1) is the most biologically active isomer. Its extraordinary environmental stability and unique ability to concentrate in animal and human tissues coupled with its extreme toxicity make dioxin a ‘model’ environmental toxicant.


Figure 1.  Chemical structure of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzofuran – two most potent chloracnegens.

Download figure to PowerPoint

2,3,7,8-Tetrachlorodibenzo-p-dioxin can elicit a complex array of pleiotropic responses in humans ranging from altered immunity to reproductive defects (1). Yet, it is only the skin effects of TCDD exposure, especially chloracne, a specific type of acne-like disease, that are the most consistent manifestation of dioxin intoxication – indeed a ‘hallmark’ of TCDD exposure (2). Owing to specific features pathognomonic for dioxin skin toxicity (high correlation of severity with the level of dioxin exposure, short incubation period, persistence and specific anatomic localization), chloracne is considered to be among the most reliable biomarkers of TCDD toxicity in humans (3). Over the past 75 years, chloracne outbreaks have occurred in the setting of industrial and non-industrial accidents involving substantial numbers of people around the world. These accidents have allowed for close observation of affected individuals over extended time periods and have helped increase our understanding of the consequences of such exposure.

The clinical features of chloracne are clearly defined and thought to relate to the non-inflammatory alteration of keratinization in the pilosebaceous unit (4–9). And yet the cellular and molecular mechanisms of dioxin-induced chloracne are still unknown. Numerous questions remain unanswered. How does chloracne differ from other acneiform skin conditions? Which skin cell populations represent the primary target of dioxin activity? What is the molecular pathway for chloracne and is it a part of the classic TCDD-dependent transcriptional mechanism that requires activation of dioxin (aryl hydrocarbon) receptor (AhR) and its binding to aryl hydrocarbon receptor nuclear translocator (ARNT)?

In 1985, Tindall (9) in an excellent review of chloracne wrote: ‘Much work has been done, but considerably more work is necessary for a complete understanding of mechanisms, response and short- and long-term risks’. Now more than 20 years later, remarkably little progress has been achieved in our understanding of this disorder.

In this review, we attempt to summarize the available clinical data and recent progress in understanding the role of dioxin and its receptor (AhR) in the modulation of gene transcription (e.g. 10–13), thus intending to delineate putative dioxin-dependent molecular pathways and cellular events that are likely involved in chloracne pathogenesis.

Chloracne – an environmental disease

  1. Top of page
  2. Abstract
  3. Introduction
  4. Chloracne – an environmental disease
  5. Dioxin – the most potent environmental chloracnegen
  6. Mechanisms of chloracne
  7. Conclusion
  8. References

Chloracne is a well-recognized but poorly understood clinical entity (5–7), characterized by an acne-like eruption of comedones (blackheads and whiteheads), cysts and pustules that occurs following systemic absorption of chemical ‘chloracnegens’.

This condition was first described in German industrial workers in the late 19th century by Von Bettman (14) and later by Herxheimer (15) who suggested that it was caused by chlorine exposure and hence coined the term ‘chloracne’ based on the similarity of its clinical features with acne vulgaris. Later, chloracne was recognized in workers employed in the production of various industrial chemicals including chlorinated phenols (16,17), polychlorinated biphenyls (PCBs) (18,19) and chlorinated naphthalenes (4), while some of these compounds in pure form are not chloracnegenic or possess low chloracnegenic activity (20). Identification of the specific ‘chloracnegenic’ factor in these mixtures remained enigmatic until trace contaminants formed during their manufacture were identified and linked to the disease (9). These contaminants include polyhalogenated dibenzofurans, dibenzo-p-dioxins and azoxybenzenes. All chloracnegenic compounds are known to share certain structural features including molecular planarity and two benzene rings with halogen atoms occupying at least three of the lateral ring positions. The position of the halogen substitutions appears to be critical, as it is known that substitutions leading to molecular non-planarity dramatically diminish chloracnegenic activity (21).

In experimental studies of polychlorinated naphthalenes applied to the skin of human volunteers, chloracne occurred in a widespread distribution, not limited to the sites of application (22). Ingestion and inhalation are also effective means of chloracne induction. Based on a study of a mass intoxication by 2,3,6,7-TCDD, it was assumed that in contrast to the other cutaneous signs of exposure to polyhalogenated aromatic compounds, chloracne is always a manifestation of systemic intoxication by chemical chloracnegens and not just a cutaneous disorder (23). The role of systemic exposure in the pathogenesis of chloracne is consistent with the very low rates of dermal absorption of chloracnegens (24). Because of their highly lipophilic nature, skin exposure to chloracnegenic compounds including dioxins results in their accumulation in the stratum corneum which in effect diminishes absorption. Removal of stratum corneum dramatically increases TCDD absorption into the skin (25). Thus, the major cause of chloracne is systemic exposure.

Clinical features

Development of chloracne lesion.  The key feature of chloracne is non-inflammatory alteration of keratinization of the pilosebaceous unit (9,26) that results in the formation of comedones, straw-coloured cysts, pustules and non-infectious abscesses that may scar (27). The patients are otherwise in good health. Pruritus is rare (28).

Chloracne usually starts as an acute erythema of the face sometimes associated with oedema (29). Erythema is followed within days by the formation of fine comedones (blackheads or whiteheads) – the most characteristic feature of chloracne (Fig. 2a). This process may involve almost every follicle in the affected area giving the involved skin a slate-gray appearance (Fig. 3a). Developing comedones start to shed hairs (Fig. 2a), while sebaceous lobules are still active, although involuting, and continue to secrete sebum (30–32).


Figure 2.  Initial stages of chloracne development. (a) Multiple blackhead comedones at different stages of formation. Most follicles are not yet turned into comedones, but nearly all of them are slightly elevated above the skin surface suggestive of high proliferation in their upper portion. In large comedones, hair shafts are lost. Note moderate erythema. (b, c) Specific localization of initial blackhead comedones in the postauricular triangle/upper neck and inside of the ear lobe.

Download figure to PowerPoint


Figure 3.  Advanced chloracne lesions. (a) With chloracne progression, nearly every hair follicle is turned into blackhead or whitehead comedones. All follicles are elevated and form a nearly continuous sheath in the affected area. Two large cysts are also seen (arrows). Note the absence of inflammatory response. (b) Cream-coloured cystic lesions on the front lobe of chloracne patient. (c) In advanced chloracne lesion, multiple blackhead comedones are seen on the cheeks, front lobe and molar crescent. The nose is spared. A large pustule is seen on the neck (arrow). (d) Healing chloracne lesion. Multiple irregular depressed scars are present along with some still active blackhead comedones.

Download figure to PowerPoint

Most investigators describing the histopathological features of chloracne have identified comedones as the primary skin lesion and suggested that squamous metaplasia of the sebaceous gland (SG) is responsible (e.g. 4,9,31).

Initially, cream-coloured cystic lesions (Fig. 3b) are less common than comedones and occur primarily on the face and neck (28,33). In long-standing lesions, non-inflammatory infundibular cysts (Fig. 3a, arrows) predominate over comedones (32) and are virtually pathognomonic of advanced chloracne (5). The cysts vary in size from 1 mm to 1 cm in diameter, and have a central orifice or pore which may not be obvious (27). In contrast to primary comedones, the pilary portion of infundibular cysts is almost always destroyed so that few or no hairs remain within the cavity. Sebaceous acini are also absent in cystic lesions (32). Involved follicles are typically surrounded by a collarette of scale (perhaps a result of infundibular hyperkeratinization) and the hair shaft is often broken and coiled. In some areas of destruction of follicular walls, a giant cell infiltrate may be present (33). These cystic lesions are virtually always sterile (32), but occasionally secondary infection of affected follicles may occur (34).

Chloracne is not associated with cutaneous inflammation (32), but in severe cases, non-infectious folliculitis can occur and the picture can resemble severe inflammatory cystic acne. This is particularly common on the back and legs (5,31). Follicular lesions in chloracne are often associated with skin thickening (32,35).

Exposure to chloracnegen action may also be associated with palmoplantar hyperkeratotic lesions of sweat gland origin (35–37). Hyperkeratinization of sweat gland duct results in acrosyringial plugging (38) similar to the plugging in the comedones of follicular origin.

Chloracne localization.  The distribution of the lesions of chloracne is very characteristic. Comedones appear most frequently on the face and neck (between 90% and 100% of affected persons) and forearms (47%), forming extensive sheaths in many cases. The most commonly involved areas are below and to the outer side of the eye (the so-called malar crescent) and in the postauricular triangles. The ear lobes, suboccipital hairline and groin are often involved (Fig. 2b,c). The cysts diminish in number as the condition extends on to the cheeks, forehead, maxillary areas and sides of the neck, whereas the nose, perioral skin and supraorbital regions are usually spared. The pustular component is usually more noticeable on the neck (Fig. 3c, arrow). Comedones and cysts can appear on the shoulders, mid-portion of the back and the chest. A peculiar peppering of the skin with tenacious carbon-coloured comedones is often apparent around the umbilicus and in lower abdomen. The outer surfaces of the forearms and anterior thighs show similar although fewer comedones. The penis may be involved in a similar process, whereas the scrotum typically shows more cystic lesions (5,31,33,34). Axillary lesions are also common in chloracne patients (31,32,39). While the overall pattern is clearly acneiform, it differs from typical acne vulgaris particularly in the diminished sebum secretion and in the peculiarly dark colour of the comedones as well as the general peppered distribution in areas not prone to acne vulgaris (4,18). In patients who ingested rice oil contaminated with PCBs (Yusho, Japan), chloracne was most severe on the face, neck and genitalia with little involvement of the extremities (37).

While virtually every hair follicle (HF) in involved areas may be affected, HFs of different types are not equally susceptible to chloracne. Vellus follicles appear to be most sensitive, whereas scalp follicles are resistant (4). Predisposition of specific types of HFs to comedogenic action of chloracnegens may be relevant to specific patterns of chloracne lesion distribution over the body.

Chloracne persistence and severity (dose–response).  The natural history of chloracne is highly variable. There is usually a delay of about 2–4 weeks from initial contact with the offending chemical to the onset of clinical lesions. In the case of intensive exposure, symptoms may appear within days (27).

With less severe intoxication, slow spontaneous improvement may begin immediately (33), but in general, assuming no further exposure, the skin lesions resolve within 2–3 years (28,37). And yet in some individuals, chloracne lesions may persist for as long as 15 years after all chemical exposures have ceased (34). According to one study, the mean duration of chloracne in workers accidentally exposed to by-products of 2,4,5-trichlorophenoxyacetic acid was 26 years, with some individuals remaining disfigured for more than three decades after the accident (40). Examination of the skin in a group of 288 Vietnamese veterans with a remote (17–22 years) history of exposure to the herbicide known as Agent Orange revealed persistent chloracne lesions in 11.5% of these subjects (41).

The chronicity of chloracne is still inexplicable. It may relate to the fact that chloracnegens are highly lipophilic and remain in body fat for sustained periods. The possible role of slow release of chloracnegens from fat cells in chloracne persistence was suggested based on the studies of Yusho patients in Japan in whom lesions persisted longer than 30 years showing a certain degree of correlation with blood levels of chloracnegens (42). Nevertheless, neither the extent nor the duration of chloracne necessarily correlates with the concentration and half-life of the chloracnegens in the body, thus suggesting alternative mechanisms. The ‘continuing modification of the metabolism of the pilosebaceous unit’ by the chloracnegen (6) seems to be a more likely explanation of chloracne persistence.

Recidivism of chloracne lesions despite total lack of further contact with the offending agent has also been reported (e.g. 30,43,44), but no satisfactory explanation for this phenomenon has been forthcoming.

The severity of chloracne depends on three major factors including (i) intensity and duration of exposure (‘dosage’), (ii) relative ‘chloracnegenic potency’ of the specific compound and (iii) ‘individual susceptibility’ (2). It is of interest that typical lesions of chloracne may occur in workers’ relatives who have never been in or near sources of exposure to chloracnegens. In these cases, the lesions were likely caused by contact with work clothes or tools which had been brought home, or from direct bodily contact (44,45), thus suggesting that in some circumstances, even trace amounts of chloracnegens may cause the disease.

Individual susceptibility to chloracne is quite variable. Experimental topical application of Halowax 1014, a mixture of hexa- and pentachloronaphthalenes (Bakelite Corp., New York, NY, USA), to the skin of volunteers showed that some subjects had no skin effects at all, whereas others developed severe chloracne. Older females appear to respond only weakly, or not at all, even to high concentrations of chronically applied chloracnegen (2). After an industrial explosion at a 2,4,5-trichlorophenol plant in Bolsover, Derbyshire, UK in April 1968, 79 cases of chloracne were recorded. In some workers, chloracne developed within days, whereas others showed no symptoms until between 2 and 3 months after the last known exposure. Younger men, particularly those of fair complexion, were first affected, while the reaction was most persistent in sallow-skinned men in the 25–40 age group. In some individuals, the condition was predominantly cystic, while in others there were comedones, such that not a single pore was uninvolved (34). In some patients, the condition was unchanged 11 months after cessation of exposure, while in others it was improving (28), thus suggesting that both the induction and recovery phases show individual patterns.

Studies of workers at trichlorophenol plants in Germany (46,47) and Czech Republic (48,49) revealed that most patients had severe chloracne, while only about one-third had additional evidence of systemic intoxication (neuropathy and liver damage). Of interest, only one patient with these symptoms had no chloracne. Thus, resistance to chloracne is quite rare.

Unfortunately, in most recorded cases of chloracne, it is not possible to attribute the differences in clinical effects (persistence and severity of the condition) to individual differences in sensitivity or to different levels of exposure. One of the few exceptions is a recent study of two patients with severe TCDD intoxication (50). In this case, one patient developed severe generalized chloracne, while another heavily intoxicated person (TCDD content of 26 000 pg/g of blood fat) showed only mild facial lesions, thus further confirming the role of individual susceptibility in the severity of the disease. Elucidation of the genetic factors determining susceptibility to chloracne is essential for understanding this condition.


Few detailed histological studies of chloracne have been published (4,18). According to these publications, the first signs of histological changes become apparent about 5 days after exposure to the chloracnegen and are associated with increased cell proliferation in the infundibular portion of the HF outer root sheath and in the SG duct along with a decrease in the number of sebocytes.

Ten days: there is dilatation of the infundibulum (especially in its lower portion); increased thickness in the upper outer root sheath that forms the infundibular walls; thickening of the SG duct that merges with the infundibulum and hyperplasia of the epidermis with incomplete keratinization as manifested by parakeratosis. No signs of SG necrosis or lysis are evident and normal-appearing sebocytes are present, but their number is substantially reduced resulting in diminishing of sebaceous lobules. Thus, chloracnegen-induced transformation of HF starts from its middle portion – around the bulge and SG duct.

Three to five weeks: small comedones appear. Only a few vellus follicles remain uninvolved. Anagen and catagen follicles are equally affected. Diffuse thickening of the middle outer root sheath progresses in all follicles and sebocytes disappear completely. Dilatation of the infundibulum is pronounced inferiorly and the cavity becomes filled by a comedo consisting of many layers of keratinized cells mixed with remaining sebum. Infundibular dilatation is maximal proximally, resulting in either bottle-shaped formations, with the neck near the surface, or columnar funnels along the entire length of the infundibular structure. Telogen stage hairs are present within the keratin mass; their bulb looks unaffected, suggesting that the lower portion of the HF does not undergo hyperplasia. The perifollicular dermis shows mild oedema and slight lymphocytic infiltration localizing around the SG or the proximal (lower) part of the infundibulum (18).

Six to twelve weeks: large comedones are apparent in all follicles from which only a few hair shafts emerge indicating hair shedding. Two types of pustules may occur: (i) deep within the dermis producing the gross swelling in which the comedo is visible centrally or (ii) superficial in which the comedo is much less prominent (Fig. 3c, arrow). In deep pustules, thinning of the outer root sheath is common, eventually resulting in rupture with extrusion of the keratin/lipid mass into the dermis, followed by a foreign-body reaction. These pustules may communicate with one another forming a carbuncle-like pattern. Healing is associated with irregular depressed scars (Fig. 3d).

Differential diagnosis: chloracne versus acne vulgaris

Based on the resemblance of the comedones and cysts that characterize chloracne to those seen in patients with severe acne vulgaris, chloracne was originally thought to represent an acne vulgaris-like disease. It is now clear that the pathogenesis of these disorders is distinctive (6,33).

Differentiating chloracne from acne vulgaris requires consideration of the clinical features, anatomic localization, age of onset and exposure history (51). The differential features of acne vulgaris and chloracne are summarized in Table 1.

Table 1.   Differential features of acne vulgaris and chloracne
 Acne vulgarisChloracne
Clinical features
 Age group affectedAdolescence and early adulthoodAny age group
 Anatomic localizationFace including the nose, upper back and chestRetroauricular and malar areas, axillae, groin, extremities; nose is spared
 InflammationInflammatory lesions are commonInflammation is very rare (only as a secondary effect after cyst rupture)
 Sebum productionIncreasedDecreased; xerosis as a common associated condition
 Initial lesionLimited comedones, papules, pustules, cystsMyriad comedones
 Sebaceous glandHypertrophicAtrophic; gradual replacement with keratinocytes
 Sweat glandUninvolvedPalmoplantar hyperkeratotic lesions; acrosyringial plugging
 Hair follicleThinning of the infundibular epithelial wallGeneral hyperplasia of the infundibulum and sebaceous gland duct; significant thickening of the upper follicle
Biochemistry and microbiology
 Biochemistry of comedonesMore free fatty acids, triglycerides and total triglyceride poolMore squalene, wax ester and cholesterol
 HormonesAndrogen dependent; testosterone and dihydrotestosterone stimulate sebum productionAntiandrogenic; the role of androgens in chloracne is unknown
 MicrofloraPropionibacterium acnes and Propionibacterium granulosum in sebaceous gland duct and hair canalNo bacteria

The anatomic distribution of chloracne is distinctive (5,31). Chloracne also differs from acne vulgaris in that it can occur in any age group, including prepubertal children (8). Epidemiological studies show no evidence that adolescent acne is a predisposing factor to developing chloracne (5). Indeed, virtually everyone with sufficient exposure to chloracnegens will develop chloracne (while the severity of the condition may be quite different, as we mentioned earlier).

Chloracne lesions rarely manifest inflammation (33), while in acne vulgaris inflammation is a common feature. The characteristic inflammation of acne vulgaris may relate to sebaceous lipids, their metabolites and by-products of the Propionibacterium acnes which are known irritants (52). P. acnes colonization is an essential feature of acne vulgaris lesions, but they are totally absent in chloracne which may explain the non-inflammatory nature of this condition (6,33).

Analysis of skin surface lipids using thin-layer chromatography reveals that in chloracne squalene, wax esters and cholesterol are increased, whereas free fatty acids, triglycerides and the total triglyceride pool are dramatically decreased (6). Skin surface cholesterol originates predominantly from keratinous structures (53) and because keratinized comedones are typically far more numerous in chloracne when compared with acne vulgaris, it is not surprising that elevated cholesterol is characteristic of chloracne. These alterations in skin surface lipids suggest that chloracnegens distort metabolic pathways in the pilosebaceous unit (6).

In chloracne patients, the skin surface is not oily. SGs are often smaller than usual or absent and sebum production is dramatically reduced (29). Thus, while the pathogenesis of acne vulgaris lesions involves excessive sebum excretion, chloracne is usually associated with cutaneous xerosis. This difference may account for the relative ineffectiveness of standard therapeutic agents for acne vulgaris in chloracne patients (33).

Elevated sebum secretion is a sine qua non for acne vulgaris and strongly correlates with the severity of the condition (54). Sebum secretion is androgen dependent, thus suggesting the involvement of androgens in pathogenesis of acne vulgaris. Both testosterone and its metabolite dihydrotestosterone (DHT) can stimulate sebum production (55,56). While the effect of TCDD and other chloracnegens on serum androgen concentration is controversial (e.g. 57–61), they have been shown to impede androgen action both in vitro and in vivo (62), probably by interfering with androgen receptors and/or by blocking androgen-induced cell proliferation through suppression of cyclin D1 and modulation of p21. TCDD mimics the action of DHT, but when TCDD and DHT are applied together, TCDD completely blocks DHT activity (62). Thus, chloracnegens appear to suppress androgen effects which is consistent with the suppression of sebogenesis seen in chloracne patients.


The similarities between chloracne and acne vulgaris have led to the use of agents effective in treating the latter in patients with the former. Topical retinoids appear to be effective comedolytic agents in acne vulgaris (6,65). Some reports have suggested that retinoids are effective in the treatment of chloracne as well (e.g. 63,64). However, a large-scale experimental study has shown that oral administration of vitamin A prior to topical application of chloracnegens to the skin of healthy volunteers neither prevents the development of chloracne nor alters the time of onset, the clinical appearance, progression of the reaction and the histology of the affected sites (4). Additional studies further confirmed that moderate and severe forms of chloracne are not sensitive to vitamin A therapy (31,33,66,67).

High doses of orally administrated corticosteroids have also proven ineffective in severe chloracne (35,66). Furthermore, it was shown that the use of steroids in the early stages of chloracne development tended to aggravate the condition (34). Despite these negative results, retinoid/corticosteroid treatment is still used to treat chloracne. Unsurprisingly, in most cases, chloracne is refractory to treatment with the usual measures employed in acne vulgaris (e.g. 33,39,44). Of these, only surgical modalities such as incision and drainage of comedones and cysts, dermabrasion and light electrodesiccation may be helpful in some chloracne patients (68).

Thus, chloracne appears to be resistant to all tested forms of treatment (34,66) and none of the occasional positive reports is supported by placebo-controlled double-blind studies. Indeed, it seems likely that the statement of Dr Linda Birnbaum (69)‘…chloracne is not curable; the only treatment we know of is time’ is perfectly true. Therefore, the only way to manage chloracne is to prevent it by eliminating any possibility of exposure to chloracnegens. Once exposure does occur, affected individuals should be removed from exposure sites and efforts made to mobilize accumulated chloracnegens from the body. Recent research by groups at the University of Vienna (70) and at the University of Western Australia (71) showed that the rate of elimination of chloracnegens can be effectively increased using a synthetic dietary fat substitute known as olestra. Natural fats consist of a triglyceride molecule with three attached fatty acids, whereas olestra is synthesized using a sucrose backbone which can bind up to eight fatty acids. As a result, there is no gastro-intestinal absorption of olestra. Chloracnegens are highly soluble in olestra, thus accelerating their fecal excretion (70). Experimental studies with mice gavaged with the 14C-labelled chloracnegen hexachlorobenzene show that combined dietary olestra and caloric restriction causes a 30-fold increase in the rate of excretion of labelled compound, relative to an ad lib diet or reduced caloric intake alone (72).

Animal models for chloracne

The interspecies differences in toxic effects of chloracnegen exposure (e.g. toxicity, thymic atrophy, etc.) are quantitative rather than qualitative (73). Surprisingly, the skin effects of these agents vary across species. Specific chloracne-like skin changes are characteristic only for rabbits (ears only) (4,74–76), primates (77) and laboratory mice carrying a mutation in the hairless (hr) gene (78). Some specific changes in the skin due to the action of dioxin-like compounds occur in cows and horses (51). Other laboratory, farm or wild animals, including extremely dioxin-sensitive species like guinea pigs, manifest no skin changes. No good explanation exists for these inter-species differences.

Rabbit ear.  Application of halogenated hydrocarbons to the inner side of the rabbit ear as a laboratory model for chloracne was first proposed by Kimmig and Schulz (74). The treatment results in the formation of numerous comedones mimicking human chloracne (74). As in the human disease, within 5–7 days after starting daily topical application of chloracnegens, follicular keratosis and hypertrophy of SG duct epithelium associated with marked shrinkage of SG acini occur (79). Gradual recovery of the pilosebaceous apparatus follows cessation of treatment (4).

Rabbit ear model is exquisitely sensitive to dioxin1 and is widely used for the evaluation of chloracnegenic potency of chemical mixtures and as a detection system for the presence of dioxin in contaminated soil and at commercial workplaces (26,80,81). Surprisingly, this model has never been used for studies of cellular and molecular mechanisms of chloracne development.

Primates.  Primate skin provides the most relevant model for human chloracne. In rhesus macaques, systemic administration of a single dose of dioxin between 30 and 70 μg/kg of body weight results in cysts and comedones typical of chloracne. According to McConnell and Moore (77), the cysts represent transformed SGs that have undergone squamous metaplasia and keratinization. Excessive growth of cysts results in their rupture with a secondary inflammatory response. Besides chloracne-like lesions, other skin effects of dioxin intoxication have been found in macaques including alopecia, loss of nail plates and significant hyperplastic and metaplastic alterations in lipid-secreting Meibomian glands (77).

Hairless mice.  The hairless (hr/hr) mouse is the only known laboratory strain that responds to dioxin treatment with symptoms strikingly similar to human chloracne (78,82–84). Hr mouse mutants show disintegration of HFs and total hair loss during the third week of postnatal life. As a result, hr mouse skin contains two unique structural remnants of the HF: (i) the utriculi, epidermis-associated comedo-like sacs derived from the HF infundibulum and (ii) closed dermal cysts. The epithelium of the utriculi in hr/hr skin is actively keratinizing, whereas the epithelium of dermal cysts displays only a low level of keratinization (85,86). Dioxin treatment induces rapid involution of utriculi and adjacent SGs without any signs of squamous transformation of sebocytes. Even at the latest stages of SG involution after the complete loss of SG structure, the remaining single sebocytes appear normal (83,87) similar to findings in human chloracne (4). Thus, dioxin-induced SG involution appears to be due to cessation of sebocyte replenishment rather than altered sebocyte differentiation.

In contrast to the utricular and SG epithelia, the dermal cyst epithelium shows hyperkeratinization after TCDD treatment (83,88,89). The resultant structures and their growth dynamic resemble the keratinized cysts characteristic of chloracne in dioxin-exposed individuals (5,33). Under TCDD action, dermal cyst epithelium normally expressing HF-specific keratin 17 (90,91) starts to express epidermis-specific keratin 1 along with total loss of keratin 17 positivity. These findings suggest that TCDD treatment results in the conversion of dermal cyst keratinocyte differentiation programme from the ‘follicular’ to the ‘epidermal’ type (83). TCDD-induced suppression of follicular and sebaceous differentiation in hr mouse skin is reversible. Cessation of TCDD treatment is followed by gradual restoration of functional SGs (87).

These data suggest that dioxin-induced chloracne-like changes in hr mice most likely reflect an imbalance in the determination of epithelial-precursor-cell fate, rather than a primary pathogenetic event in the SG or dermal cyst.

Horses and cows.  In both these species, exposure to chloracnegens (chlorinated naphthalenes) results in extensive hyperkeratosis (or ‘X disease’), abnormal growth of hooves and (only in horses) Meibomian gland abnormalities (92,93). Some of these symptoms resemble certain effects of dioxin intoxication in humans and primates, but no clinical or experimental studies have been performed in farm animals ever since and whether they are able to develop chloracne-like lesions under dioxin exposure is still not known. In 1971, accidental intoxication of horses with dioxin-containing chemicals in Missouri resulted in alopecia (22 horses) and skin ulcers (16 horses). Half of the animals died (94,95).

Dioxin – the most potent environmental chloracnegen

  1. Top of page
  2. Abstract
  3. Introduction
  4. Chloracne – an environmental disease
  5. Dioxin – the most potent environmental chloracnegen
  6. Mechanisms of chloracne
  7. Conclusion
  8. References

Dioxins became infamous as an occupational cause of chloracne after a trichlorophenol reactor explosion in 1949 in Nitro, West Virginia (22). Later, it was suggested that dioxins may be the major chloracnegenic factor in various polyhalogenated chemical formulations (96) and soon thereafter, a series of studies were undertaken to elucidate their chemical and toxic properties (74,97). But it was not until the 1970s that dioxins were studied in detail when extreme toxicity of TCDD became apparent (20) and large numbers of people were exposed to its action in several industrial accidents around the world. This was also abetted by the extensive exposure of American veterans to TCDD-containing defoliants including Agent Orange during the Vietnam War (e.g. 98,99).

Dioxin fate in the environment

Chemically, TCDD (C12H4O2Cl4; molecular weight 322 g/mol) is very stable and resistant to photolysis, chemical oxidants and heat up to 800°C. It is highly soluble in organic solvents (especially in o-dichlorobenzene) and practically insoluble in water. Its half-life in soil is about 1.5 years (100), but in river and lake sediments, it may remain for decades (101) and is a source of enduring exposure for aquatic organisms. One of the most critical chemical features of TCDD is its extraordinary lipophilicity (102) and associated ability to concentrate in terrestrial and aquatic food chains reaching very high concentrations in the tissues of birds of prey, seals and humans (103–105).

2,3,7,8-Tetrachlorodibenzo-p-dioxin is formed as a by-product during the combustion of chlorine-containing materials and during high-temperature reactions of industrial organic synthesis utilizing chlorine (106). While some believe that environmental TCDD originated from forest fires and home furnaces (107), TCDD was first detected in stratified lake and swamp sediments dating to the 1930s (108,109), a time when mass production of multiple polyhalogenated aromatic compounds was just beginning. These findings support the largely industrial origin of the TCDD in the environment.

The initial source of TCDD was the production of polychlorophenol-based wood preservatives. Later, during WW II, the first herbicides with hormone-like action were developed in the USA based on 2,4-dichlor (2,4-D) and 2,4,5-trichlorphenoxyacetic (2,4,5-T) acids. In the 1960s, the production of 2,4-D and 2,4,5-T increased substantially and soon reached its peak due to the extensive use of these herbicides during the Vietnam War. Between 1962 and 1971, about 15 million gallons of a mixture containing both 2,4-D and 2,4,5-T known as Agent Orange was used as a defoliant in Vietnam. The average concentration of TCDD in Agent Orange was about 3 μg/ml (110). The total amount of TCDD released into the environment during the Vietnam War was estimated to be about 500 kg (99).

By the 1970s, the production of phenoxyacetic acids and other halogenated hydrocarbons such as DDT and the PCBs was banned in the United States and in most European countries, but the environmental release of TCDD continued nonetheless. For example, the total TCDD deposition flux to the Great Lakes in 1996 was estimated at about 57 g (111). Although this may seem like a very small amount, 57 g of dioxin is equivalent to 1 year of the World Health Organization's defined Tolerable Daily Intake of TCDD for approximately one billion people.2

Currently, the most significant sources of dioxin contamination are combustion of municipal wastes; chemical industrial processes; metal smelting; the use of motor oil with chlorine-containing additives; paper bleaching; and continuing production of polychlorophenols, PCBs and chlorophenoxyacetic acid-based herbicides in some developing countries (107,112).

Routes of human exposure, metabolism and bioaccumulation

The major route of dioxin intake is dietary (up to 95%) and the average daily consumption of TCDD is estimated to be in the range of 30–200 pg in Europe (113) and 50 pg in the USA (114) resulting in average content in human tissues about 4–6 p.p.t. (115). Dioxin half-life in the human body is estimated to be 7–11 years (116,117).

Due to increasingly stringent regulations, dioxin emissions in the US decreased by ≈80% between 1987 and 1995 (118). At the same time, some individuals may be at unique risk to dioxin exposure. For example, in a study conducted in Sweden, it was found that people regularly eating fish in the diet showed a fourfold higher concentration of TCDD in blood serum compared with people eating fish occasionally (119). Workers in the textile, paper, leather industry, weed control, capacitor production and waste incineration may also be at high risk (110).

Measurement of TCDD content in adipose tissue of the general population in the USA (more than 800 people) showed that tissue TCDD residues increase with age (120). Levels in males significantly exceed those in females (121). Breast-feeding may be a significant source of TCDD exposure for newborns (122).

Dioxin toxicity: interspecies differences

2,3,7,8-Tetrachlorodibenzo-p-dioxin is among the most toxic substances known, at least for laboratory animals (20,123). At the same time, dioxin toxicity varies substantially in different species (Table 2). These differences impede the direct extrapolation of observations in laboratory animals to humans. Nevertheless, based on taxonomic consanguinity, it was proposed that dioxin lethal dose, 50% (LD50) for humans is comparable with the toxicity level identified in monkeys (70–280 μg/kg of body weight) (77), thus greatly exceeding the human toxicity of other poisons including sarin, cyanides, strychnine and curare.

Table 2.   Dioxin LD50 values for different animal species (263 with additions)
AnimalLD50 (μg/kg body weight, oral)
Mink female0.3
Mink male4.2
Guinea pig0.5–1
Rat male22
Rat female45

Dioxin toxicity in animals has some peculiar features. One of them is its lengthy latency. Laboratory rodents die within 3 weeks of a lethal dose, whereas in larger animals the delay is greater, for example, up to 6 weeks in monkeys (124). Then, except for animals with severe liver necrosis (chicken and rabbits), the immediate cause of death cannot be attributed to a specific organ or system pathology and remains unclear for most tested animal species. Finally, the total dose of TCDD required to evoke a pathological response is less if the dose is administered over time when compared with a single dose.

Clinical symptoms of TCDD toxic action

In laboratory animals, TCDD causes hyperplasia of epithelial tissues including the skin, bile duct, digestive and genito-urinary tracts. It also results in generalized oedema of internal organs; hepatomegaly; thymus, bone marrow and testis atrophy; and immunosuppression (125–127). Exposed animals exhibit a wasting syndrome that resembles starvation or anorexia (128,129). It was found that TCDD is an active promoter of two-step carcinogenesis in rodent liver (130,131) and skin (132,133). Dioxin also induces embryotoxic and teratogenic effects in mice such as cleft palate and abnormalities of kidney development (128).

The human toxicity of TCDD is poorly understood. Some reports describe a broad spectrum of effects including emphysema, myocardial degeneration, toxic nephritis, hypertension, peripheral oedema, anorexia, gastritis, bursitis and intolerance to cold (30,43,134). A wide range of neurological symptoms have also been reported, including peripheral neuropathy, paraesthesias, headaches, vertigo, coordination disturbances, loss of libido, easy fatigability and emotional instability (135,136). The carcinogenic and teratogenic effects of TCDD documented in animals have not been verified in humans despite its designation by the International Agency for Research on Cancer as a class 1 carcinogen, meaning a ‘known human carcinogen’. At the same time, no case of lethal human poisoning with TCDD has been reported and most data on its human toxicity are speculative. The only specific, sensitive, consistent and long-lasting sign of human TCDD intoxication is chloracne (1,9,137).

The threat of TCDD for human health is beyond any doubt, but the level of its danger is still undefined (138). Further insight into cellular and molecular mechanisms of TCDD action in target tissues would provide better understanding of the potential risk of TCDD exposure.

Dioxin-induced molecular pathways

Canonical (AhR/ARNT) pathway.  Many, if not all, of the effects of TCDD in humans and animals appear to be mediated by the AhR, a member of the basic-helix-loop-helix (bHLH) period-ARNT-single-minded (Per-ARNT-Sim) (PAS) family of dimeric transcription factors (139,140). This receptor was identified as a factor essential for cytochrome P4501A1-mediated induction of several liver enzymes by TCDD treatment (141). The subunit composition of the AhR took years to resolve, due to the low levels of receptor expression (e.g. 100–1000 fmol/mg protein) combined with its inherent instability (142). Nevertheless, extensive work from many laboratories has yielded a comprehensive model for TCDD–AhR signalling (Fig. 4).


Figure 4.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)–aryl hydrocarbon receptor (AhR)–aryl hydrocarbon receptor nuclear translocator (ARNT) signalling. As a typical Per–ARNT–Sim (PAS) protein, AhR possesses transactivation domain, PAS domain which includes the ligand-binding sequence and a basic-helix-loop-helix region. In cytosol, AhR is complexed with a dimer of Hsp90, hepatitis B virus X-associated protein 2 and p23 protein. Ligand (TCDD) binding by the AhR results in the nuclear translocation and release of Hsp90 and other partner proteins, followed by dimerization with ARNT. TCDD/AhR/ARNT complex binds xenobiotic responsive element (GCGTG) resulting in transactivation.

Download figure to PowerPoint

According to this model, the unliganded AhR exists in the cytosol in a tetrameric complex, consisting of the AhR ligand-binding subunit, a dimer of the 90 kDa heat shock protein (Hsp90) (143,144), and the hepatitis B virus X-associated protein 2 (XAP2), an immunophilin-related protein (145). XAP2 stabilizes the AhR and plays a role in sequestering the non-liganded AhR in the cytoplasm by an as-yet uncharacterized mechanism (146). Hsp90 functions as a molecular chaperone and plays a key role in the proper folding and stability of the non-liganded AhR, thus maintaining a high-affinity ligand-binding conformation for the receptor and preventing nuclear translocation and/or dimerization (147–149). Another factor required for the stability of non-liganded AhR is p23 that is thought to stabilize the latent receptor–hsp90 heterocomplex, thus playing the role of a co-chaperone (150–152).

After passive diffusion into target cells, TCDD binds hsp90/XAP2/p23-associated AhR, thereby initiating receptor complex conformational transformation which results in a receptor species with increased affinity for DNA and a much slower rate of ligand dissociation (153). This event is associated with nuclear translocation of the activated complex during which hsp90 and the other proteins dissociate from the TCDD/AhR complex and are exchanged for ARNT. Heterodimerization of AhR with ARNT – another helix-loop-helix PAS protein which is a central dimerization partner in the family of PAS transcription factors (154) – results in the formation of a transcriptionally active dimer. The AhR–ARNT heterodimer recognizes a specific DNA sequence 5′-GCGTGNA/T-3′′, called the dioxin response element, located in the promoter region of certain genes, thus resulting in their transactivation (155). One such gene is CYP1A1, encoding the cytochrome P4501A1 protein, which has proven to be a useful biomarker of exposure to dioxin-type chemicals in many animal species (156). Using CYP1A1 as a model system, it has been shown that AhR/ARNT-induced transactivation depends on the activity of multiple coactivators that bind AhR and/or ARNT and provide a bridge between heterodimer and general transcription factors located in the promoter of the regulated gene. These cofactors include Sp1, nuclear coactivators (Ncoa1,2,3), coactivator receptor interacting protein (RIP)-140, retinoblastoma protein, Myb binding protein (Mybbp1a), promyelocytic leukemia (PML) and others (reviewed in Ref. 11).

In addition to Cyp1A1 induction, the AhR/ARNT heterodimer also mediates other biological effects of TCDD including teratogenesis, tumor promotion and immunosuppression mainly affecting skin, liver and the nervous system (132,139,157). The downstream target genes for AhR/ARNT heterodimers mediating these effects are mostly unknown.

Although originally thought to have a relatively narrow structural specificity (158), the AhR is now known to recognize a broad array of chemical structures, including non-aromatic and non-halogenated compounds (140). Nonetheless, it is paradoxical that the endogenous ligand for AhR is still undefined and its physiological functions other than xenobiotic metabolism still remain to be elucidated.

Substantial insight into AhR function was obtained by generating two Ahr ‘null’ mouse strains using a gene targeting strategy (159,160). Despite some minor phenotypic differences, these strains exhibit strikingly similar features including decreased liver size, subtle hepatic portal fibrosis, decreased constitutive expression of cytochrome P4501A2 and decreased body size during the first 4 weeks of life. Ahr-null mice are resistant to TCDD-induced toxicity, thus confirming the role of the Ahr gene in mediating TCDD-dependent pathways (161) and yet some TCDD effects seem to be Ahr independent (162,163). Most studies of Ahr-null mice have focused on their response to dioxins. However, these knockout experiments also reveal that the Ahr plays important roles during early development in such tissues as the liver, eye and kidney (164,165). Six- to 12-month-old Ahr-null mice also have progressive, focal lesions on the dorsal skin associated with alopecia and ulceration (164). The skin phenotype in Arnt-null mice is consistent with the finding that AhR is expressed in epidermal keratinocytes in a differentiation-associated manner (166).

The studies with recombinant inbred mice revealed four allelic variants of Ahr among laboratory strains. The highest susceptibility to toxic effects of TCDD segregates with the Ahrb1 allele, which occurs in the prototype ‘responsive’ strain, C57BL/6. ‘Non-responsive’ mice, such as the prototype DBA/2 strain, represent the Ahrd allele with a 10-fold lower affinity for TCDD compared with Ahrb1 allele and are much less sensitive to toxic and biochemical effects of TCDD action (167). Functional polymorphism was also shown for human AhR gene (168). Potential association of this polymorphism with individual differences in susceptibility to chloracne is still unknown.

Alternative molecular pathways of dioxin toxicity.  The AhR–ARNT transcriptional activation pathway is now considered to be the primary mediator of TCDD biological action (reviewed in Refs 158,169). Nevertheless, none of the genes currently known as targets for the AhR/ARNT dimer can explain the pleiotropic effects of dioxin toxicity, including the skin symptoms. Thus, while there is strong experimental evidence for initial TCDD binding to the AhR, several alternative explanations exist for the subsequent biochemical events which lead to the pleiotropic toxic effects of dioxin (170).

Some believe that dioxin-induced toxicity is mediated by activation of the epidermal growth factor receptor (EGFR), based on the observation that dioxin effects resemble those of epidermal growth factor (EGF) such as early eye opening and incisor eruption, loss of body weight (‘wasting syndrome’), epithelial hyperplasia and retardation of hair growth (171–173). According to this concept, dioxin binding to AhR activates the protein tyrosine kinase pp60src (c-Src), which amplifies EGF signalling (174). This dioxin effect is thought to be AhR mediated but ARNT independent (175,176). It seems plausible that some elements of TCDD toxicity, particularly those related to the growth factor-like syndrome, could be mediated by AhR-induced activation of c-Src independently of ARNT (177). In this scheme, activated c-Src kinase is proposed to trigger various cellular responses, particularly those involved in the growth factor signal transduction pathway (178,179). The precise mechanism of dioxin signalling transduction by AhR to activate c-Src is not known.

Downstream molecular targets of TCDD-dependent pathways.  While the initial molecular events evoked by TCDD are relatively well understood, the downstream effects and molecular targets of TCDD activity are not well defined. During the last decade, numerous studies have been performed using differential display in human and mouse hepatoma cells treated with TCDD or its antagonists (e.g. 180,181). These studies identified two major functional pathways: toxic and stress related as the main targets of TCDD activity, findings consistent with the classic (AhR/ARNT) mechanism of TCDD toxicity.

The first pathway includes a battery of phase I and phase II xenobiotic metabolizing enzymes, such as CYP1A1, CYP1A2 and CYP1B1 (encoding cytochromes P4501A1, -1A2 and -1B1, respectively), glutathione S-transferase, UDP-glucuronosyltransferase and NADPH:quinone oxidoreductase (157,182). All of these genes are induced by TCDD and other chloracnegens via AhR/ARNT and play an essential role in both metabolic activation and detoxification of TCDD and other xenobiotics including polycyclic aromatic hydrocarbons (183). Whether induction of P4501A1 and other detoxifying enzymes is causally linked to dioxin toxic effects remains unclear.

Another functional TCDD-dependent downstream pathway includes genes independent of detoxification and implicated in the control of stress response and developmental processes. Among them, plasminogen activator inhibitor-2 (PAI-2) (184,185) and a wide range of growth factors and their receptors (186) have been identified, thus further suggesting that AhR may have physiological roles independent of xenobiotic metabolism (187).

2,3,7,8-Tetrachlorodibenzo-p-dioxin-dependent growth factors include: (i) EGF which shows a significant decrease of binding capacity in the hepatic plasma membrane due to TCDD action (188); (ii) EGFR that is dramatically upregulated in palatal epithelium of TCDD-exposed mouse newborns resulting in a high incidence of cleft palate (189,190); (iii) transforming growth factor (TGF)-α which is increased in TCDD-treated primary human keratinocytes (186), but is actively downregulated by TCDD during mouse palatogenesis in vivo (190); (iv) TGF-β2 which is strongly suppressed by TCDD in vitro (191,192), but in vivo (embryogenesis) is up- or downregulated by TCDD depending on the state of fetal development (193); (v) TGF-β3 which is upregulated by TCDD in a dose-dependent manner in vitro (187); (iv) interleukin-1β (IL-1β) which is positively regulated by TCDD (184) and possesses a prominent antagonism on TCDD-induced effects (194); (7) tumor necrosis factor (TNF) which seems to mimic TCDD action (195,196) and is upregulated by TCDD (123,197), thus suggesting that acute toxicity of TCDD may be mediated by TNF (198).

The role of TCDD in cell cycle regulation through transactivation of p27 and jun-B as well as in apoptosis control through Bax transactivation is also established (157,199,200).

The studies of TCDD-dependent expression in vivo are quite limited and have been performed in only a few organs and tissues including liver, lung, thymus, spleen and the reproductive system of laboratory animals (e.g. 201). Despite their limited number, these studies have revealed several genes not previously shown by in vitro experiments. The major targets of TCDD activity in vivo were not only cytokines and growth factors like EGFR, TGF-β and different interleukins (201,202) but also genes implicated in apoptotic and angiogenic pathways. Among TCDD-regulated apoptotic genes are Fas ligand, caspases, several genes of Bcl-2 family and TNF-related apoptosis-inducing ligand, while angiogenesis-related genes include vascular endothelial growth factor (VEGF), the plasminogen activator cascade (PAI-1, PAI-2, PLAU and PLAUR) and angiogenin (201). In the reproductive system, dioxin-inducible factor-3 was identified as one of the major TCDD targets (203).

In summary, TCDD exposure results in altered expression of many growth factors, cytokines, apoptotic and angiogenic factors that could provide explanations for TCDD effects on proliferation and differentiation signals in the skin. At the same time, little evidence is available to link these expressional changes to the specific TCDD-induced skin pathology.

TCDD effects on epithelial cells in culture.  The establishment of adequate in vitro experimental model is of paramount importance for elucidating the mechanisms of dioxin action in skin. A survey of 23 transformed human epithelial cell lines yielded none that could be used as a model to study TCDD-induced chloracne. All examined cell lines displayed no changes in morphology, viability or growth patterns following TCDD exposure despite profound upregulation of xenobiotic-metabolizing enzymes like CYP1A1 (204).

Studies of TCDD-treated primary human keratinocytes cultured in monolayer have shown equivocal results (205–208). No difference in sensitivity to dioxin was also found between primary keratinocytes isolated from HRS/J haired and hairless (hr/hr) mouse skin (209) that manifest strikingly different sensitivity to TCDD in vivo. Thus, traditional monolayer cultures lacking the structural and functional complexity of intact skin appear to be incapable of answering questions pertaining to chloracne. In contrast, by using a three-dimensional epithelial organotypic culture system, it was shown that 8 days’ postplating, dioxin-treated cultures possess a well-developed cornified layer that was absent in controls (210). Dioxin-treated cultures displayed a more flattened morphology specific for suprabasal keratinocytes, earlier onset of filaggrin expression and evidence of more active keratinization. Involucrin expression was evident in many basal keratinocytes, a feature never observed in control cultures (210). Thus, TCDD exerts profound effects on keratinocyte differentiation in vitro, but these effects require conditions or factors present in vivo or in organotypic culture and lacking in monolayer cultures. The potential role of such ‘epicellular factors’ in the maintenance of skin homeostasis is supported by a strong line of evidence. For example, studies using co-cultures of keratinocytes and dermal fibroblasts have clearly demonstrated active production of mutually inductive growth factors that impact proliferation in both epithelial and mesenchymal cells and modulate expression of structural proteins and epithelial architecture (211,212). The pivotal role of epithelial–mesenchymal communication in the control of HF cycling and hair growth is now an axiom (213,214).

The role of AhR in TCDD-induced changes in organotypic cultures of human skin keratinocytes is not well defined. CYP1A1 mRNA expression can be induced in an AhR-dependent manner in the absence of any xenobiotic, simply by altering the adhesive characteristics of the cells. A similar response can be achieved by suspending keratinocytes in semisolid medium in the absence of a xenobiotic (215). Suspension ablates both cell–cell and cell–substrate contacts and is a technique used to mimic the process of keratinocyte differentiation in which basal cells must modify their adhesive characteristics in order to migrate upward. Suspension culture triggers a variety of changes in gene expression parallel to those observed during keratinocyte differentiation. The novel observation that genes classically associated with xenobiotic-metabolizing enzymes can be induced in the absence of a xenobiotic simply by modifying cellular adhesive characteristics is critical because it suggests that AhR/ARNT signal transduction participates not only in detoxification but also in normal physiological pathways. This dual role for AhR signal transduction in skin was originally proposed soon after AhR was identified as the mediator of TCDD toxicity (216).

Dioxin effects on sebocytes are of particular interest because sebocyte differentiation is severely affected following dioxin exposure in vivo (31,87). It is known that TCDD abrogates adipogenesis in primary mouse embryo fibroblasts (217) and affects lipid metabolism in laboratory rodents and in humans (218,219). Nevertheless, the effects of TCDD on sebocyte differentiation in human skin remain to be defined.

Molecular targets for TCDD activity in the skin.  The data on potential molecular targets of TCDD activity in skin in vivo are very limited. The exposure of mouse fetuses to TCDD caused premature expression of filaggrin and increased expression of involucrin at E16, thus suggesting that an AhR-dependent pathway is a modulator of terminal differentiation in fetal mouse skin (220). Topical application of TCDD to hr mice results in ectopic expression of epidermal-specific keratin 1 and loss of HF-specific keratin 17 in dermal cyst epithelia, suggesting a toxin-induced conversion of their differentiation programme from the ‘follicular’ to the ‘epidermal’ type (83).

Recently, it was shown that constitutive activation of AhR pathway is sufficient to trigger inflammatory skin lesions in mice with activation of IL-18 and chemokine C–C motif ligand 20 as the primary mechanism (221). As these effects were induced by ligand-independent upregulation of AhR expression, the possible role of TCDD in the control of these genes in vivo remains unknown.

Mechanisms of chloracne

  1. Top of page
  2. Abstract
  3. Introduction
  4. Chloracne – an environmental disease
  5. Dioxin – the most potent environmental chloracnegen
  6. Mechanisms of chloracne
  7. Conclusion
  8. References

Cellular targets of dioxin activity in the skin

The major effect induced by TCDD in different skin structures (Table 3) is alteration of cellularity that results in prominent hyperplastic or hypoplastic responses. Thus, different epithelial structures in the skin respond to TCDD differentially: epidermis and infundibulum (which is characterized by epidermal-like type of differentiation) undergo prominent hyperplasia; sebaceous and sweat glands lose their secretory activity and are replaced by keratinizing cells, while the lower portion of the follicle (hair bulb) gradually involutes. Each cellular target of dioxin activity in skin possesses one common feature – they all represent endpoints of distinctive differentiation programs characteristic of HF pluripotent stem cells or their immediate progeny – transit-amplifying cells. The balance between these differentiation pathways is tightly regulated by still poorly understood signal transduction pathways (e.g. 222–224). Hypoplasia of some skin epithelial structures along with prominent hyperplasia in others in response to dioxin suggests that the pathogenesis of TCDD-induced chloracne may involve alteration of stem cell homeostasis and lineage commitment. The following lines of evidence support this concept.

Table 3.   Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) upon different epithelial structures in human and mouse skins
Skin structureTCDD-induced effect
Infundibulum and sebaceous gland (SG) duct (upper hair follicle)Hyperplasia
SGHypoplasia, complete disappearance
Sweat glandAcrosyringial plugging; the palmoplantar hyperkeratotic lesions; hyperhidrosis
Hair bulbHypoplasia
  • 1
    Chloracne is a persistent process that remains years after chemical exposure (67). The involvement of long-lived stem cells in chloracne pathogenesis would provide an exhaustive explanation for the chronic course of this condition. The involvement of stem cells is also consistent with the delayed onset of chloracne after exposure to the inducing chemicals.
  • 2
    The first signs of TCDD-induced hyperproliferation in human and mouse skin are visible in the lowermost part of the permanent portion of the HF (4,83,225) – the region where HF stem cells are located (226). Other TCDD-responsive cell compartments in skin including epidermis, SG duct, sweat gland duct and lower HF outer root sheath all harbor populations of cells with high proliferative potential – early transit-amplifying cells (227–229).
  • 3
    It is a common view that chloracne is associated with alterations of sebocyte differentiation and the gradual transformation of these cells into keratinizing cells which results in squamous metaplasia of SGs (e.g. 30). But neither human nor animal (hr mice and rabbit ear) studies provide any morphological evidence for the transformation of sebocytes to keratinocytes. Instead, in chloracnegen-exposed skin, sebocytes differentiate normally. But once they complete their holocrine cycle, they are not replenished and are gradually replaced by keratinizing cells coming from the SG duct or outer root sheath (4,29,45,225).
  • 4
    Dermal cysts, a specific feature of hr mouse skin, originate from cells representing remnants of the HF bulge. They express HF-specific keratins and are capable of sebaceous differentiation (86). TCDD treatment induces loss of HF-specific keratin 17 and ectopic expression of epidermal keratin 1 in dermal cyst epithelium, thus suggesting a switch from a pilosebaceous to an epidermal differentiation pattern in precursor cells (83). The resulting abrogation of sebocyte replenishment and their replacement with immigrating keratinocytes in hr mouse skin are identical to the process of comedo formation in human chloracne.
  • 5
    The TCDD-dependent molecular pathway is relevant to haematopoietic stem cell (HSC) homeostasis and lineage commitment. Studies in C57BL/6J mice (230) show that HSCs are significantly elevated following TCDD treatment and demonstrate a marked shift in lineage commitment with reduced capacity of bone marrow to generate pro-T lymphocytes. AhR-dependent TCDD-induced proliferation of HSC (exit from stem cell compartment) and the shift in their differentiation lineage commitment are a major cause of TCDD-induced thymic atrophy (230,231) that occurs in many mammalian species (232). The cellular kinetics of TCDD-induced thymus atrophy is highly reminiscent of TCDD-induced transformation in utricle epithelium and SG of hr mice (83) and in pilosebaceous units in chloracne patients and in rabbit ear skin (4).
  • 6
    It was suggested that AhR, like other bHLH-PAS family members, plays a role in the formation or maintenance of three-dimensional tissue structure in skin (210). On the other hand, three-dimensional structure of the epidermis and HF is an outcome of sophisticated sequence of epithelial–mesenchymal communications which in turn is a key mechanism of HF stem cell control. Nevertheless, direct evidence of AhR/ARNT pathway implication in epithelial–mesenchymal signalling is still lacking.

Based on the above evidence, we propose that chloracnegen-induced transformation of the pilosebaceous unit is driven by activation and accelerated exit of cells from the stem cell compartment coupled with a shift from a pilosebaceous differentiation pattern to an epidermal one. This may result in imbalance in early multipotent cells’ commitment and their preferential differentiation along an epidermal lineage with consequent diminution of SG and lower HF portion along with prominent epidermal/infundibular hyperplasia and hyperkeratinization. This model is highly consistent with the pattern of morphological changes in the skin of both chloracne patients (32,35) and animal models of chloracne (4,83,225). Hyperplasia of the infundibulum along with the switch of its content from semiliquid sebum to solid keratin could explain infundibulum dilation and comedo development. Similar mechanism is likely involved in TCDD-induced transformation of eccrine sweat glands which are also known to be a target of chloracnegen activity (35).

In summary, the multipotent HF stem cell concept (226,228) provides a comprehensive basis for understanding TCDD-induced changes in human and hr mouse skin and can help explain the histopathological differences between chloracne and acne vulgaris: while the latter is associated with exaggerated sebogenesis, chloracne is associated with redirection of pilosebaceous differentiation pathways to epidermal type, thus resulting in exaggerated keratinization and a switch from sebaceous to keratinized comedones.

Putative molecular mechanisms of chloracne development

The potential role of AhR/ARNT interactions in pathogenesis of TCDD-induced skin lesions.  Despite clear evidence documenting the involvement of AhR/ARNT dimerization in TCDD toxicity in such target tissues as lungs, liver and thymus, the role of this dimer in mediating skin effects of TCDD action is still unclear.

First, the testing of different chloracnegens in hr mouse skin revealed no clear correlation between the level of chloracnegen affinity to the Ahr and the skin response. All tested compounds that did not bind the Ahr did not exhibit any skin effects. Nevertheless, some compounds with high affinity to the Ahr had little or no effect on hr mouse skin (233). Then, TCDD effects on potent regulators of epithelial homeostasis– the oncogenes c-fos and c-jun – are thought to be Ahr independent (163), suggesting that the skin effects of TCDD, at least in part, may also be Ahr independent.

On the other hand, in hr mice, the susceptibility to TCDD-induced epidermal hyperplasia strongly segregates with the AhRb1 allele (233) suggests direct involvement of AhR in the development of skin effects of TCDD toxicity at least in hr skin. The high level of AhR expression and its direct correlation with keratinocyte differentiation in human epidermis (166) support the possible involvement of AhR in chloracne pathogenesis also in humans. Yet, clear proof of this assumption is still lacking.

The crucial role of ARNT in several regulatory pathways implicated in response to the environmental insult (234–236) suggests that ARNT may be a key element of skin-environment communication, yet very little is known about the function(s) of ARNT in the skin (237). It was shown that ARNT is essential for such effects of TCDD action as thymic involution (238) and induction of xenobiotic-metabolizing enzymes including CYP1A1, CYP1A2 and UDP-glucuronosyltransferases (239), but its potential role in pathogenesis of TCDD-induced skin effects was never assessed. Nevertheless, essential role of many AhR/ARNT-dependent genes in the maintenance of skin homeostasis indirectly suggests that AhR/ARNT heterodimerization may be a prerequisite of chloracne pathogenesis as well.

Fig. 5 summarizes the potential mechanisms of AhR and ARNT involvement in the pathogenesis of chloracne. The downstream targets of AhR/ARNT activity include the complex of xenobiotic-metabolizing enzymes, PAI-2, IL-1β and other growth factors and cytokines (184,240) that play a role in the maintenance of skin homeostasis. TCDD-activated AhR may also compete for ARNT with other ARNT-binding factors (e.g. hypoxia inducible factor (Hif) 1α), thus reducing its availability for other interactions, not directly dependent on AhR activity. This pathway may suppress erythropoietin, VEGF, platelet-derived growth factor and glycolytic enzymes (155). The binding of TCDD with AhR may compete with as-yet unidentified endogenous AhR ligand. The ARNT-independent direct activation of the protein kinase cascade by TCDD/AhR complex (177) may also represent a molecular mechanism of chloracne induction because its downstream targets (e.g. EGFR, c-Myc, IL-1β, PAI-2, p53, MMP1, etc.) are known to be involved in regulating epithelial cell proliferation and differentiation (241–245).


Figure 5.  Potential mechanisms of aryl hydrocarbon receptor (AhR) and aryl hydrocarbon receptor nuclear translocator (ARNT) implication in molecular pathogenesis of chloracne. Red arrows – ARNT-mediated pathways; blue arrows – ARNT-independent pathways.

Download figure to PowerPoint

Stem cell recruitment and lineage commitment as potential targets of TCDD activity in the skin.  Among all existing attempts to provide an explanation for the puzzling features of chloracne, we wish to highlight the notion by Cunliffe et al. (6) who proposed that chloracne is determined by ‘the continuing modification of the metabolism of the pilosebaceous unit’ by the chloracnegen. Although this proposition was made long before the advent of the concept of HF stem cell, it invokes the existence of long-lived, stable cell population in the HF which can propagate the impact of the chloracnegen over several hair cycles (which normally last in humans about 3–5 years). Only stem cells fulfill these requirements. In itself, Cunliffe's prescient recognition of stable, long-living modification of the HF as the major cause of chloracne sheds little light on the pathomechanism of this disease. However, in conjunction with the HF stem cell concept, it provides a basis for a totally new approach to further explore the mechanisms of TCDD action upon skin.

According to the current concept, all epithelial structures in mammalian skin are maintained throughout the adult life by stem cells that not only generate daughter cells that undergo terminal differentiation along several pathways specific for every skin epithelial lineage but also self-renew (228,246). During the last decade, solid evidence has been obtained pointing at the bulge region of the HF as the primary niche for the skin stem cell population (247,248). There is reason to believe that the nature and location of stem cells may differ between HF types. Stem cells are normally quiescent or slow cycling [over 14 months in the mouse; (249)], but in response to certain stimuli like wounding or still mysterious hair cycle-inducing signals, they can be recruited into proliferation. Another set of still poorly understood signals determines the specific pattern of differentiation for resulting transit-amplifying cells. As a result, epidermal, SG or hair matrix progenitor cells are replenished by direct progeny of HF stem cell population (228).

As we mentioned before, pathogenesis of TCDD-induced chloracne suggests the following stem cell-associated events (Fig. 6): (i) recruitment of stem cells into cycling and their active exit into transit-amplifying cell compartment that probably determine hyperplasia in the middle portion of chloracne follicles; (ii) elevated level of stem cell renewal that maintains the sufficient number of stem cells even under their active exit into proliferating compartment, thus probably determining the persistence of chloracne; (iii) the shift in the fate of transit-amplifying cells – differentiation along epidermal pathway at the expense of HF and sebaceous differentiation.


Figure 6.  The hypothetical model for potential cellular and molecular mechanisms of chloracne development based on the model of role of c-Myc in skin stem cell control (222, 265). 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)/aryl hydrocarbon receptor complex modulate c-Myc activity through one of the putative upstream c-Myc regulatory cascades (c-Src, Wnt, TGFβ). That results in the recruitment of stem cells into proliferation and in differentiation of their progeny (transit amplifying cells) mainly along epidermal lineage at the expense of follicular differentiation. Along with simultaneous suppression of sebaceous differentiation, this results in the formation of keratinizing comedones. TCDD action can also stimulate hair follicle stem cell renewal, thus determining chloracne persistence.

Download figure to PowerPoint

Recently, it was shown that transient activation of a nuclear protooncogene c-Myc in mouse skin drives keratinocytes from the stem to the transit-amplifying compartment and stimulates differentiation along the epidermal and sebaceous lineage at the expense of hair-type differentiation (222,223,250). It was also found that the increased proliferation in the basal layer was not dependent on continuous activation of transgene. ‘Thus, transient activation of c-myc could result in sustained effects on the behaviour of keratinocytes’ (222,223). This model of c-Myc effects on HF stem cells is also supported by the finding that ablation of β-catenin, genetically upstream of c-Myc, prevents cycling of HFs by forcing stem cells into an epidermal fate (224).

Thus, the general scheme of c-Myc-dependent changes in the kinetics of HF stem cells fits the main features of TCDD-induced skin phenotype, while some noticeable differences also exist. For example, deregulation of c-Myc expression stimulates transit-amplifying cells to adopt epidermal and sebaceous fates in the expense of HF differentiation (222,250), although TCDD action stimulates epidermal differentiation at the expense of both, HF and sebaceous lineages. This difference suggests that if c-Myc pathway is a target of TCDD activity in the skin, its deregulation is not the only mechanism of chloracne pathogenesis. This proposition is also supported by partial, not complete, similarity between skin phenotype in transgenic mice overexpressing c-Myc (222) and chloracne-like symptoms in laboratory animals (83).

Currently, little is known about possible interactions between AhR/ARNT and c-Myc pathways. c-Myc is tightly regulated by growth factors and has been shown to be inhibited by the TGF-β2 signalling (251,252) which in turn is strongly suppressed by TCDD in vitro (191,192), suggesting potential positive influence of TCDD upon c-Myc expression. On the other hand, TCDD is a potent suppressor of c-Myc-induced apoptosis in Alb/c-Myc transgenic mice (253). In the liver of TCDD-treated guinea pigs, c-Myc DNA binding is downregulated (254). Treatment of 3T3-L1 preadipocyte cells in vitro (pretreated with TCDD) with antisense c-Myc oligonucleotides blocked the toxic effects of TCDD (255).

Another possible link between TCDD/AhR and c-Myc may be represented by c-Src/β-catenin pathway that plays an essential role in HF and skin biology (256). Although c-Src, a well-known target of TCDD action (177), does not directly participate in c-Myc phosphorylation, it phosphorylates tyrosine residues of β-catenin, leading to its extensive degradation (257). β-catenin, in turn, is a known upstream modulator of c-Myc expression (258–260). The role of β-catenin as a linker in the c-Src/c-myc signal transduction pathway in epithelial tissues is also confirmed by a significant increase in the tyrosine phosphorylation state of β-catenin in renal epithelial cells under c-Src activation (261).

Thus, existing data strongly suggest that c-Myc/Max and TCDD/AhR signalling pathways are linked together, but mechanisms of their interaction are still unclear.

According to our model of chloracne pathogenesis, TCDD not only induces the recruitment of stem cells into proliferation but also stimulates stem cell renewal, thus driving chloracne persistence. Although some genes involved in Wnt signalling, adhesion and transcriptional regulation have been proposed as possible candidates to play a role in self-renewal of HF stem cells (262), the mechanisms of this regulation remain largely unknown. Therefore, the possible role of TCDD/AhR pathway in the maintenance of stem cell population also remains obscure.

Thus, based on the data presented above and taking into account the scheme for the role of c-Myc in skin stem cell control (263), we propose that the primary mechanism of chloracne may be represented by TCDD-induced stimulation of keratinocytes to exit from the stem to the transit-amplifying cell compartment, resulting in hyperplasia. This exit is asymmetrical, with differentiation of resultant cells mainly along the epidermal lineage at the expense of pilosebaceous differentiation. We further suggest the AhR/c-Src/c-Myc cascade as the likely dioxin-induced signal transduction pathway leading to chloracne (Fig. 6). Predisposition of specific types of HFs to chloracne may relate to differential dynamics of stem cell activity in various types of follicles.

It is our hope that this model will provide a blueprint for future studies and that step-by-step testing of the assertions put forth in our review will lead to the disclosure of molecular and cellular pathways of chloracne development.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Chloracne – an environmental disease
  5. Dioxin – the most potent environmental chloracnegen
  6. Mechanisms of chloracne
  7. Conclusion
  8. References

Chloracne is the most specific and sensitive biomarker of dioxin intoxication that allows clinical and epidemiological evaluation of exposure level at the threshold dose for humans. This is an extremely important fact in evaluating large groups of people exposed to unknown chemicals, or where the magnitude of exposure cannot be determined. Thus, the elucidation of cellular and molecular mechanisms of this clinical condition is essential for understanding and controlling the impact of polyhalogenated environmental toxicants on the general population and on specific risk groups like chemical workers and military forces.

Discovery of the genes directly implicated in the TCDD-dependent pathway of skin toxic response would have far-reaching implications for the development of new methods of chloracne differential diagnosis and therapy. This will also provide a solid basis for the identification of the genetic basis of differential human susceptibility to chloracnegen action and improvement of occupational health standards.

Furthermore, the studies of the role of AhR-dependent regulatory pathways in skin biology may open a new avenue in understanding the basic mechanisms maintaining skin stem cell homeostasis.

  • 1

    The minimal comedogenic topical dose of dioxin for the rabbit ear was estimated at 80 ng (80 × 10−9 g) (19,78).

  • 2

    The World Health Organization has determined that the Tolerable Daily Intake of dioxin is 1–4 pg/kg of total body weight per day.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Chloracne – an environmental disease
  5. Dioxin – the most potent environmental chloracnegen
  6. Mechanisms of chloracne
  7. Conclusion
  8. References
  • 1
    Sweeney M H, Mocarelli P. Human health effects after exposure to 2,3,7,8-TCDD. Food Addit Contam 2000: 17: 303316.
  • 2
    Suskind R R. Chloracne, ‘‘the hallmark of dioxin intoxication’’. Scand J Work Environ Health 1985: 11: 165171.
  • 3
    Feeley M M. Biomarkers for Great Lakes priority contaminants: halogenated aromatic hydrocarbons. Environ Health Perspect 1995: 103 (Suppl. 9): 716.
  • 4
    Hambrick G W. The effect of substituted naphthalenes on the pilosebaceous apparatus of rabbit and man. J Invest Dermatol 1957: 28: 89103.
  • 5
    Crow K D. A critical review, including a comparison of two series of acne from chloronaphthalene and pitch fumes. Trans St Johns Hosp Dermatol Soc 1970: 56: 7999.
  • 6
    Cunliffe W J, Williams M, Edwards J C et al. An explanation for chloracne – an industrial hazard. Acta Derm Venereol 1975: 55: 211214.
  • 7
    Taylor J S. Environmental chloracne: update and overview. Ann N Y Acad Sci 1979: 320: 295307.
  • 8
    Dunagin W G. Cutaneous signs of systemic toxicity due to dioxins and related chemicals. J Am Acad Dermatol 1984: 10: 688700.
  • 9
    Tindall J P. Chloracne and chloracnegens. J Am Acad Dermatol 1985: 13: 539558.
  • 10
    Carlson D B, Perdew G H. A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 2002: 16: 317325.
  • 11
    Hankinson O. Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch Biochem Biophys 2005: 433: 379386.
  • 12
    Puga A, Tomlinson C R, Xia Y. Ah receptor signals cross-talk with multiple developmental pathways. Biochem Pharmacol 2005: 69: 199207.
  • 13
    Pocar P, Fischer B, Klonisch T, Hombach-Klonisch S. Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. Reproduction 2005: 129: 379389.
  • 14
    Bornemann W. Ueber die histologie der chloracne. Arch Derm Res 1902: 62: 7590.
  • 15
    Herxheimer K. Uber chloracne. Munch Med Wochenschr 1899: 46: 278.
  • 16
    Hofmann H T. Neuere Erfahrungen mit hochtoxischen Chlorkohlenwasserstoffen. Arch Exp Pathol Pharmakol 1957: 232: 228230.
  • 17
    Behrbohm P. Hazards in use of chlorinated phenols. Dtsch Gesundheitsw 1959: 14: 614619.
  • 18
    Jones J W, Alden H S. An acneform dermatergosis. Arch Derm Syphilol 1936: 33: 10221034.
  • 19
    Schwartz L. Dermatitis from synthetic resins and waxes. Am J Public Health 1936: 26: 586592.
  • 20
    Schwetz B A, Norris J M, Sparschu G L et al. Toxicology of chlorinated dibenzo-p-dioxins. Environ Health Perspect 1973: 5: 8799.
  • 21
    English J S, Dawe R S, Ferguson J. Environmental effects and skin disease. Br Med Bull 2003: 68: 129142.
  • 22
    Zack J A, Suskind R R. The mortality experience of workers exposed to tetrachlorodibenzodioxin in a trichlorophenol process accident. J Occup Med 1980: 22: 1114.
  • 23
    Goldman P J. Severe acute chloracne – a mass intoxication by 2,3,6,7-tetrachlorobenzodioxin. Hautartz 1973: 24: 149152.
  • 24
    Banks Y B, Birnbaum L S. Absorption of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) after low dose dermal exposure. Toxicol Appl Pharmacol 1991: 107: 302310.
  • 25
    Weber L W, Zesch A, Rozman K. Penetration, distribution and kinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human skin in vitro. Arch Toxicol 1991: 65: 421428.
  • 26
    Zugerman C. Chloracne. Clinical manifestations and etiology. Dermatol Clin 1990: 8: 209213.
  • 27
    Taylor J S. Chloracne – a continuing problem. Cutis 1974: 13: 585591.
  • 28
    Jensen N E. Chloracne: three cases. Proc R Soc Med 1972: 65: 687688.
  • 29
    Jensen N E, Sneddon I B, Walker A E. Tetrachlorobenzodioxin and chloracne. Trans St Johns Hosp Dermatol Soc 1972: 58: 172177.
  • 30
    Schulz K H. Clinical picture and etiology of chloracne. Arbeits Med Socialmed Arbeitshyg 1968: 3: 25.
  • 31
    Crow K D. Chloracne. Semin Dermatol 1982: 1: 305314.
  • 32
    Pastor M A, Carrasco L, Izquierdo M J et al. Chloracne: histopathologic findings in one case. J Cutan Pathol 2002: 29: 193199.
  • 33
    McDonagh A J, Gawkrodger D J, Walker A E. Chloracne – study of an outbreak with new clinical observations. Clin Exp Dermatol 1993: 18: 523525.
  • 34
    May G. Chloracne from the accidental production of tetrachlorodibenzodioxin. Br J Ind Med 1973: 30: 276283.
  • 35
    Geusau A, Jurecka W, Nahavandi H, Schmidt J B, Stingl G, Tschachler E. Punctate keratoderma-like lesions on the palms and soles in a patient with chloracne: a new clinical manifestation of dioxin intoxication? Br J Dermatol 2000: 143: 10671071.
  • 36
    Poskitt L B, Duffill M B, Rademaker M. Chloracne, palmoplantar keratoderma and localized scleroderma in a weed sprayer. Clin Exp Dermatol 1994: 19: 264267.
  • 37
    Kuratsune M, Yoshimura T, Matsuzaka J, Yamaguchi A. Yusho, a poisoning caused by rice oil contaminated with polychlorinated biphenyls. HSMHA Health Rep 1971: 86: 10831091.
  • 38
    Caputo R, Monti M, Ermacora E et al. Cutaneous manifestations of tetrachlorodibenzo-p-dioxin in children and adolescents. Follow-up 10 years after the Seveso, Italy, accident. J Am Acad Dermatol 1988: 19: 812819.
  • 39
    Crow K D. Chloracne and its potential clinical implications. Clin Exp Dermatol 1981: 6: 243257.
  • 40
    Moses M, Lilis R, Crow K D et al. Health status of workers with past exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in the manufacture of 2,4,5-trichlorophenoxyacetic acid: comparison of findings with and without chloracne. Am J Ind Med 1984: 5: 161182.
  • 41
    Panteleyev A A, Roumak V S, Stepanova L V, Poznyakov S P, Bocharov B V. Clinical and ultrastructural characterization of human skin after exposure to dioxin-contaminated defoliants. Proceedings of Joint Russian–Vietnam Tropical Centre, Moscow, 1991: 300304.
  • 42
    Uenotsuchi T, Nakayama J, Asahi M et al. Dermatological manifestations in Yusho: correlation between skin symptoms and blood levels of dioxins, such as polychlorinated debenzofurans (PCDFs) and polychlorinated biphenyls (PCBs). J Dermatol Sci Suppl 2005: 1: S73S80.
  • 43
    Bauer H, Schulz K H, Spregelberg U. Occupational intoxications in manufacturing chlorophenol compounds. Arch Gewerbepathol 1961: 18: 538555.
  • 44
    Taylor J S, Wuthrich R C, Lloyd K M, Poland A. Chloracne from manufacture of a new herbicide. Arch Dermatol 1977: 113: 616619.
  • 45
    Braun W. Clinical observations on the pathogenesis of chloracne. Hautarzt 1959: 10: 126129.
  • 46
    Huff J E, Moore J A, Saracci R, Tomatis L. Long-term hazards of polychlorinated dibenzodioxins and polychlorinated dibenzofurans. Environ Health Perspect 1980: 36: 221240.
  • 47
    Thiess A M, Frentzel-Beyme R, Link R. Mortality study of persons exposed to dioxin in a trichlorophenol-process accident that occurred in the BASF AG on November 17, 1953. Am J Ind Med 1982: 3: 179189.
  • 48
    Pazderova-Vejlupkova J, Lukas E, Nemcova M, Pickova J, Jirasek L. The development and prognosis of chronic intoxication by tetrachlordibenzo-p-dioxin in men. Arch Environ Health 1981: 36: 511.
  • 49
    Jirasek L, Kalensky J, Kubec K, Pazderova J, Lukas E. Chloracne, porphyria cutanea tarda, and other poisonings due to the herbicides. Hautarzt 1976: 27: 328333.
  • 50
    Geusau A, Abraham K, Geissler K, Sator M O, Stingl G, Tschachler E. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: clinical and laboratory effects. Environ Health Perspect 2001: 109: 865869.
  • 51
    Kimbrough R D. Skin lesions in animals and humans: a brief overview. In: PolandA, KimbroughR D, eds. Banbury Report 18: Biological Mechanisms of Dioxin Action. Cold Spring Harbour: Cold Spring Harbor Laboratory, 1984: 357363.
  • 52
    Leyden J J. New understandings of the pathogenesis of acne. J Am Acad Dermatol 1995: 32: S15S25.
  • 53
    Cunliffe W J, Cotterill J A, Williamson B. Variations in skin surface lipid composition with different sampling techniques. Br J Dermatol 1971: 85: 4045.
  • 54
    Strauss J S, Pochi P E, Downing D T. Acne: perspectives. J Invest Dermatol 1974: 62: 321325.
  • 55
    Pochi P E, Strauss J S. Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol 1974: 62: 191201.
  • 56
    Imperato-McGinley J, Gautier T, Cai L Q, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993: 76: 524528.
  • 57
    Sweeney M H, Calvert G M, Egeland G A, Fingerhut M A, Halperin W E, Piacitelli L A. Review and update of the results of the NIOSH medical study of workers exposed to chemicals contaminated with 2,3,7,8-tetrachlorodibenzodioxin. Teratog Carcinog Mutagen 1997: 17: 241247.
  • 58
    Johnson E, Shorter C, Bestervelt L et al. Serum hormone levels in humans with low serum concentrations of 2,3,7,8-TCDD. Toxicol Ind Health 2001: 17: 105112.
  • 59
    Simanainen U, Adamsson A, Tuomisto J T et al. Adult 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure and effects on male reproductive organs in three differentially TCDD-susceptible rat lines. Toxicol Sci 2004: 81: 401407.
  • 60
    Fukuzawa N H, Ohsako S, Wu Q et al. Testicular cytochrome P450scc and LHR as possible targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the mouse. Mol Cell Endocrinol 2004: 221: 8796.
  • 61
    Haavisto T E, Myllymaki S A, Adamsson N A et al. The effects of maternal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin on testicular steroidogenesis in infantile male rats. Int J Androl 2006: 29: 313322.
  • 62
    Barnes-Ellerbe S, Knudsen K E, Puga A. 2,3,7,8-Tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. Mol Pharmacol 2004: 66: 502511.
  • 63
    Plewig G. Local treatment of chlorine acne (halowax acne) with vitamin A acid. Hautarzt 1970: 21: 465470.
  • 64
    Plewig G. Vitamin A acid therapy in chlorine acne. Which practical way can be recommended in vitamin A acid therapy of chlorine acne? Hautarzt 1971: 22: 370.
  • 65
    Shuster S. Acne: the ashes of a burnt out controversy. Acta Derm Venereol Suppl 1985: 120: 4346.
  • 66
    Gawkrodger D J. Chloracne: causation, diagnosis and treatment. J Dermatol Treat 1991: 2: 7376.
  • 67
    Scerri L, Zaki I, Millard L G. Severe halogen acne due to a trifluoromethylpyrazole derivative and its resistance to isotretinoin. Br J Dermatol 1995: 132: 144148.
  • 68
    Yip J, Peppall L, Gawkrodger D J, Cunliffe W J. Light cautery and EMLA in the treatment of chloracne lesions. Br J Dermatol 1993: 128: 313316.
  • 69
    Birnbaun LS The mechanism of dioxin toxicity: relationship to risk assessment. Environ Health Perspect 1994: 102 (Suppl. 9): 157167.
  • 70
    Geusau A, Tschachler E, Meixner M et al. Olestra increases faecal excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Lancet 1999: 354: 12661267.
  • 71
    Redgrave T G, Wallace P, Jandacek R J, Tso P. Treatment with a dietary fat substitute decreased Arochlor 1254 contamination in an obese diabetic male. J Nutr Biochem 2005: 16: 383384.
  • 72
    Jandacek R J, Anderson N, Liu M, Zheng S, Yang Q, Tso P. Effects of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. Am J Physiol Gastrointest Liver Physiol 2005: 288: G292G299.
  • 73
    Skene S A, Dewhurst I C, Greenberg M. Polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans: the risks to human health. A review. Hum Toxicol 1989: 8: 173203.
  • 74
    Kimmig J, Shulz K H. Berufliche Akne (sog. Chlorakne) durch chlorierte aromatische zyklische Äther. Dermatologica 1957: 115: 540546.
  • 75
    Van Den Berg K J, Zurcher C, Brouwer A, Van Bekkum D W. Chronic toxicity of 3,4,3′,4′-tetrachlorobiphenyl in the marmoset monkey (Callithrix jacchus). Toxicology 1988: 48: 209224.
  • 76
    McConnell E E, Hass J R, Altman N, Moore J A. A spontaneous outbreak of polychlorinated biphenyl (PCB) toxicity in rhesus monkeys (Macaca mulatta): toxicopathology. Lab Anim Sci 1979: 29: 666673.
  • 77
    McConnell E E, Moore J A. Toxicopathology characteristics of the halogenated aromatics. Ann N Y Acad Sci 1979: 320: 138150.
  • 78
    Inagami K, Koga T, Kikuchi M, Hashimoto M, Takahashi H, Wada K. Experimental study of hairless mice following administration of rice oil used by a ‘‘Yusho’’ patient. Fukuoka Acta Med 1969: 60: 548553.
  • 79
    Hambrick G W, Blank H. A microanatomical study of the response of the pilosebaceous apparatus of the rabbit's ear canal. J Invest Dermatol 1956: 26: 185200.
  • 80
    Adams E M, Irish D D, Spencer H C, Rowe W K. The response of rabbit skin to compounds reported to have caused acneiform dermatitis. Ind Med 1941: 2: 14.
  • 81
    Jones E L, Krizek H. A technic for testing acegenic potency in rabbits, applied to the potent acnegen, 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Invest Dermatol 1962: 39: 511517.
  • 82
    Poland A, Knutson J C, Glover E. Histologic changes produced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in the skin of mice carrying mutations that affect the integument. J Invest Dermatol 1984: 83: 454459.
  • 83
    Panteleyev A A, Thiel R, Wanner R et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCCD) affects keratin 1 and keratin 17 gene expression and differentially induces keratinization in hairless mouse skin. J Invest Dermatol 1997: 108: 330335.
  • 84
    Panteleyev A A, Paus R, Ahmad W, Sundberg J P, Christiano A M. Molecular and functional aspects of the hairless (hr) gene in laboratory rodents and humans. Exp Dermatol 1998: 7: 249267.
  • 85
    Montagna W, Chase H B, Melaragno H P. The skin of hairless mice. 1. The formation of cysts and the distribution of lipids. J Invest Dermatol 1952: 19: 8394.
  • 86
    Panteleyev A A, Van Der Veen C, Rosenbach T, Muller-Rover S, Sokolov V E, Paus R. Towards defining the pathogenesis of the hairless phenotype. J Invest Dermatol 1998: 110: 902907.
  • 87
    Panteleyev A A, Rosenbach T, Paus R, Christiano A M. The bulge is the source of cellular renewal in the sebaceous gland of mouse skin. Arch Dermatol Res 2000: 292: 573576.
  • 88
    Puhvel S M, Sakamoto M, Ertl D C, Reisner R M. Hairless mice as models for chloracne: a study of cutaneous changes induced by topical application of established chloracnegens. Toxicol Appl Pharmacol 1982: 64: 492503.
  • 89
    Puhvel S M, Sakamoto M. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on murine skin. J Invest Dermatol 1988: 90: 354358.
  • 90
    McGowan K M, Coulombe P A. Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development. J Cell Biol 1998: 143: 469486.
  • 91
    Panteleyev A A, Paus R, Wanner R et al. Keratin 17 gene expression during the murine hair cycle. J Invest Dermatol 1997: 108: 324329.
  • 92
    Gregory R P, Wise J C, Sikes D. Experimental production of bovine hyperkeratosis with a feed concentrate exposed to vapors of a highly chlorinated naphthalene. J Am Vet Med Assoc 1954: 125: 244246.
  • 93
    Vlahos K, McEntee K, Olafson P, Hansel W. Destruction and restoration of spermatogenesis in a bull experimentally poisoned with highly chlorinated naphthalene. Cornell Vet 1955: 45: 198209.
  • 94
    Carter C D, Kimbrough R D, Liddle J A et al. Tetrachlorodibenzodioxin: an accidental poisoning episode in horse arenas. Science 1975: 188: 738740.
  • 95
    Kimbrough R D, Carter C D, Liddle J A, Cline R E. Epidemiology and pathology of a tetrachlorodibenzodioxin poisoning episode. Arch Environ Health 1977: 32: 7786.
  • 96
    Schulz K H. Klinische und experimentelle Untersuchungen zur Ätiologie der Chlorakne. Arch Klin Exp Dermatol 1957: 206: 589596.
  • 97
    Sandermann W, Stockmann H, Casten R. Über die Pyrolise des Pentachlorphenols. Chem Ber 1957: 90: 690692.
  • 98
    Wolfe W H, Michalek J E, Miner J C et al. Health status of Air Force veterans occupationally exposed to herbicides in Vietnam. I. Physical health. JAMA 1990: 264: 18241831.
  • 99
    Westing A H, Pfeiffer E W. Dioxins in Vietnam. Science 1995: 270: 217.
  • 100
    Ramel C. Chlorinated phenoxy acids and their dioxins. Ecol Bull. Stockholm: Swedish Natural Science Research Council, 1978: 27: 302.
  • 101
    Isensee A R, Jones G E. Distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in aquatic model ecosystem. Environ Fate 1975: 9: 668672.
  • 102
    Schroy J M, Hileman F D, Cheng S C. Physical/chemical properties of 2,3,7,8-TCDD. Chemosphere 1985: 14: 877880.
  • 103
    Corsolini S, Focardi S, Kannan K, Tanabe S, Tatsukawa R. Isomer-specific analysis of polychlorinated biphenyls and 2,3,7,8-tetrachlorodibenzo-p-dioxin equivalents (TEQs) in red fox and human adipose tissue from central Italy. Arch Environ Contam Toxicol 1995: 29: 6168.
  • 104
    Corsolini S, Kannan K, Imagawa T, Focardi S, Giesy J P. Polychloronaphthalenes and other dioxin-like compounds in Arctic and Antarctic marine food webs. Environ Sci Technol 2002: 36: 34903496.
  • 105
    Kannan K, Corsolini S, Imagawa T, Focardi S, Giesy J P. Polychlorinated-naphthalenes, -biphenyls, -dibenzo-p-dioxins, -dibenzofurans and p,p′-DDE in bluefin tuna, swordfish, cormorants and barn swallows from Italy. Ambio 2002: 31: 207211.
  • 106
    Bumb R R, Crummett W B, Cutie S S et al. Trace chemistries of fire: a source of chlorinated dioxins. Science 1980: 210: 385390.
  • 107
    Spiro T G, Thomas V M. Sources of dioxin. Science 1994: 266: 349 (author reply 350–352).
  • 108
    Czuczwa J, McVeety B, Hites R. Polychlorinated dibenzo-p-dioxins and dibenzofurans in sediments from Siskiwit Lake, Isle Royale. Science 1984: 226: 568569.
  • 109
    Czuczwa J, Niessen F, Hites R. Historical record of polychlorinated dibenzo-p-dioxins and dibenzofurans in Swiss lake sediments. Chemosphere 1985: 14: 11751179.
  • 110
    Schecter A, Papke O, Ball M, Lis A, Brandt-Rauf P. Dioxin concentrations in the blood of workers at municipal waste incinerators. Occup Environ Med 1995: 52: 385387.
  • 111
    Cohen M D, Draxler R R, Artz R et al. Modeling the atmospheric transport and deposition of PCDD/F to the Great Lakes. Environ Sci Technol 2002: 36: 48314845.
  • 112
    Hutzinger O, Choudhry G G, Chittim B G, Johnston L E. Formation of polychlorinated dibenzofurans and dioxins during combustion, electrical equipment fires and PCB incineration. Environ Health Perspect 1985: 60: 39.
  • 113
    Geyer H, Scheunert I, Korte F. Bioconcentration potential of organic environmental chemicals in humans. Regul Toxicol Pharmacol 1986: 6: 313347.
  • 114
    Travis C C, Hattemer-Frey H A. Human exposure to dioxin. Sci Total Environ 1991: 104: 97127.
  • 115
    Schecter A, Cramer P, Boggess K et al. Intake of dioxins and related compounds from food in the U.S. population. J Toxicol Environ Health A 2001: 63: 118.
  • 116
    Pirkle J L, Wolfe W H, Patterson D G et al. Estimates of the half-life of 2,3,7,8-tetrachlorodibenzo-p-dioxin in Vietnam Veterans of Operation Ranch Hand. J Toxicol Environ Health 1989: 27: 165171.
  • 117
    Wolfe W H, Michalek J E, Miner J C et al. Determinants of TCDD half-life in veterans of operation ranch hand. J Toxicol Environ Health 1994: 41: 481488.
  • 118
    EPA US. Dioxin: Summary of the Dioxin Reassessment Science. Duluth, MN: EPA US, June 12, 2000.
  • 119
    Svensson B G, Nilsson A, Hansson M, Rappe C, Akesson B, Skerfving S. Exposure to dioxins and dibenzofurans through the consumption of fish. N Engl J Med 1991: 324: 812.
  • 120
    Orban J E, Stanley J S, Schwemberger J G, Remmers J C. Dioxins and dibenzofurans in adipose tissue of the general US population and selected subpopulations. Am J Public Health 1994: 84: 439445.
  • 121
    Andrews J S, Garrett W A, Patterson D G et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin levels in adipose tissue of persons with no known exposure and in exposed persons. Chemosphere 1989: 18: 499506.
  • 122
    Koppe J G. Dioxins and furans in the mother and possible effects on the fetus and newborn breast-fed baby. Acta Paediatr Scand Suppl 1989: 360: 146153.
  • 123
    Vos J G, Kreeftenberg J G, Engel H W, Minderhoud A, Van Noorle Jansen L M. Studies on 2,3,7,8-tetrachlorodibenzo-p-dioxin induced immune suppression and decreased resistance to infection: endotoxin hypersensitivity, serum zinc concentrations and effect of thymosin treatment. Toxicology 1978: 9: 7586.
  • 124
    Neal R A, Olson J R, Gasiewicz T A, Geiger L E. The toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mammalian systems. Drug Metab Rev 1982: 13: 355385.
  • 125
    Gupta G N, Vos J G, Moore J A, Zinkl J G, Bullock B C. Pathologic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals. Environ Health Perspect 1973: 15: 125140.
  • 126
    Luster M I, Faith R E, Lawson L D. Effects of 2,3,7,8-tetrachlorodibenzofuran (TCDF) on the immune system in guinea pigs. Drug Chem Toxicol 1979: 2: 4960.
  • 127
    Kimbrough R D. Determining exposure and biochemical effects in human population studies. Environ Health Perspect 1983: 48: 7779.
  • 128
    Birnbaum L S, Morrissey R E, Harris M W. Teratogenic effects of 2,3,7,8-tetrabromodibenzo-p-dioxin and three polybrominated dibenzofurans in C57BL/6N mice. Toxicol Appl Pharmacol 1991: 107: 141152.
  • 129
    Tuomisto J T, Pohjanvirta R, Unkila M, Tuomisto J. TCDD-induced anorexia and wasting syndrome in rats: effects of diet-induced obesity and nutrition. Pharmacol Biochem Behav 1999: 62: 735742.
  • 130
    Kociba R J, Keyes D G, Beyer J E et al. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 1978: 46: 279303.
  • 131
    Toth K, Somfai-Relle S, Sugar J, Bence J. Carcinogenicity testing of herbicide 2,4,5-trichlorophenoxyethanol containing dioxin and of pure dioxin in Swiss mice. Nature 1979: 278: 548549.
  • 132
    DiGiovanni J, Viaje A, Berry D L, Slaga T J, Juchau M R. Tumor-initiating ability of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Arochlor 1254 in the two-stage system of mouse skin carcinogenesis. Bull Environ Contam Toxicol 1977: 18: 552557.
  • 133
    Poland A, Palen D, Glover E. Tumour promotion by TCDD in skin of HRS/J hairless mice. Nature 1982: 300: 271273.
  • 134
    DeVito M J, Birnbaum L S, Farland W H, Gasiewicz T A. Comparisons of estimated human body burdens of dioxin-like chemicals and TCDD body burdens in experimentally exposed animals. Environ Health Perspect 1995: 103: 820831.
  • 135
    Goetz C G, Bolla K I, Rogers S M. Neurologic health outcomes and Agent Orange: Institute of Medicine report. Neurology 1994: 44: 801809.
  • 136
    Bertazzi P A, Bernucci I, Brambilla G, Consonni D, Pesatori A C. The Seveso studies on early and long-term effects of dioxin exposure: a review. Environ Health Perspect 1998: 106 (Suppl. 2): 625633.
  • 137
    Mukerjee D. Health impact of polychlorinated dibenzo-p-dioxins: a critical review. J Air Waste Manag Assoc 1998: 48: 157165.
  • 138
    Stone R. Dioxin report faces scientific gauntlet. Science 1994: 265: 1650.
  • 139
    Hahn M. Aryl hydrocarbon receptors: diversity and evolution. Chem Biol Interact 2002: 141: 131160.
  • 140
    Denison M S, Nagy S R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003: 43: 309334.
  • 141
    Poland A, Glover E, Kende A S. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J Biol Chem 1976: 251: 49364946.
  • 142
    Petrulis J R, Perdew G H. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem Biol Interact 2002: 141: 2540.
  • 143
    Perdew G H. Association of the Ah receptor with the 90-kDa heat shock protein. J Biol Chem 1988: 263: 1380213805.
  • 144
    Denis M, Cuthill S, Wikstrom A C, Poellinger L, Gustafsson J A. Association of the dioxin receptor with the Mr 90,000 heat shock protein: a structural kinship with the glucocorticoid receptor. Biochem Biophys Res Commun 1988: 155: 801807.
  • 145
    Meyer B K, Perdew G H. Characterization of the AhR–hsp90–XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry 1999: 38: 89078917.
  • 146
    Kazlauskas A, Poellinger L, Pongratz I. The immunophilin-like protein XAP2 regulates ubiquitination and subcellular localization of the dioxin receptor. J Biol Chem 2000: 275: 4131741324.
  • 147
    Henry E C, Gasiewicz T A. Transformation of the aryl hydrocarbon receptor to a DNA-binding form is accompanied by release of the 90 kDa heat-shock protein and increased affinity for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem J 1993: 294: 95101.
  • 148
    Chen H S, Perdew G H. Subunit composition of the heteromeric cytosolic aryl hydrocarbon receptor complex. J Biol Chem 1994: 269: 2755427558.
  • 149
    Carver L A, Jackiw V, Bradfield C A. The 90-kDa heat shock protein is essential for Ah receptor signaling in a yeast expression system. J Biol Chem 1994: 269: 3010930112.
  • 150
    Cox M B, Miller C A III. The p23 co-chaperone facilitates dioxin receptor signaling in a yeast model system. Toxicol Lett 2002: 129: 1321.
  • 151
    Shetty P V, Bhagwat B Y, Chan W K. P23 enhances the formation of the aryl hydrocarbon receptor–DNA complex. Biochem Pharmacol 2003: 65: 941948.
  • 152
    Hollingshead B D, Petrulis J R, Perdew G H. The aryl hydrocarbon (Ah) receptor transcriptional regulator hepatitis B virus X-associated protein 2 antagonizes p23 binding to Ah receptor–Hsp90 complexes and is dispensable for receptor function. J Biol Chem 2004: 279: 4565245661.
  • 153
    Bradfield C A, Kende A S, Poland A. Kinetic and equilibrium studies of Ah receptor-ligand binding: use of [125I]2-iodo-7,8-dibromodibenzo-p-dioxin. Mol Pharmacol 1988: 34: 229237.
  • 154
    Swanson H I, Bradfield C A. The AH-receptor: genetics, structure and function. Pharmacogenetics 1993: 3: 213230.
  • 155
    Schmidt J V, Bradfield C A. Ah receptor signaling pathways. Annu Rev Cell Dev Biol 1996: 12: 5589.
  • 156
    Elferink C J, Whitlock J P Jr. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-inducible, Ah receptor-mediated bending of enhancer DNA. J Biol Chem 1990: 265: 57185721.
  • 157
    Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003: 1619: 263268.
  • 158
    Poland A, Knutson J C. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol 1982: 22: 517554.
  • 159
    Fernandez-Salguero P, Pineau T, Hilbert D M et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995: 268: 722726.
  • 160
    Schmidt J V, Su G H, Reddy J K, Simon M C, Bradfield C A. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci U S A 1996: 93: 67316736.
  • 161
    Fernandez-Salguero P M, Hilbert D M, Rudikoff S, Ward J M, Gonzalez F J. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 1996: 140: 173179.
  • 162
    Lin T M, Ko K, Moore R W, Buchanan D L, Cooke P S, Peterson R E. Role of the aryl hydrocarbon receptor in the development of control and 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed male mice. J Toxicol Environ Health A 2001: 64: 327342.
  • 163
    Hoffer A, Chang C Y, Puga A. Dioxin induces transcription of fos and jun genes by Ah receptor-dependent and -independent pathways. Toxicol Appl Pharmacol 1996: 141: 238247.
  • 164
    Fernandez-Salguero P M, Ward J M, Sundberg J P, Gonzalez F J. Lesions of aryl-hydrocarbon receptor-deficient mice. Vet Pathol 1997: 34: 605614.
  • 165
    Lahvis G P, Lindell S L, Thomas R S et al. Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc Natl Acad Sci U S A 2000: 97: 1044210447.
  • 166
    Wanner R, Panteleyev A, Henz B M, Rosenbach T. Retinoic acid affects the expression rate of the differentiation-related genes aryl hydrocarbon receptor, ARNT and keratin 4 in proliferative keratinocytes only. Biochim Biophys Acta 1996: 1317: 105111.
  • 167
    Okey A B, Vella L M, Harper P A. Detection and characterization of a low affinity form of cytosolic Ah receptor in livers of mice nonresponsive to induction of cytochrome P1-450 by 3-methylcholanthrene. Mol Pharmacol 1989: 35: 823830.
  • 168
    Harper P A, Wong J Y, Lam M S, Okey A B. Polymorphisms in the human AH receptor. Chem Biol Interact 2002: 141: 161187.
  • 169
    Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995: 35: 307340.
  • 170
    Dunlap D Y, Ikeda I, Nagashima H, Vogel C F, Matsumura F. Effects of src-deficiency on the expression of in vivo toxicity of TCDD in a strain of c-src knockout mice procured through six generations of backcrossings to C57BL/6 mice. Toxicology 2002: 172: 125141.
  • 171
    Madhukar B V, Brewster D W, Matsumura F. Effects of in vivo-administered 2,3,7,8-tetrachlorodibenzo-p-dioxin on receptor binding of epidermal growth factor in the hepatic plasma membrane of rat, guinea pig, mouse, and hamster. Proc Natl Acad Sci U S A 1984: 81: 74077411.
  • 172
    Matsumura F. How important is the protein phosphorylation pathway in the toxic expression of dioxin-type chemicals? Biochem Pharmacol 1994: 48: 215224.
  • 173
    Kohn M C. Biochemical mechanisms and cancer risk assessment models for dioxin. Toxicology 1995: 102: 133138.
  • 174
    Bombick D W, Matsumura F. 2,3,7,8-Tetrachlorodibenzo-p-dioxin causes elevation of the levels of the protein tyrosine kinase pp60c-src. J Biochem Toxicol 1987: 2: 141154.
  • 175
    Sewall C H, Clark G C, Lucier G W. TCDD reduces rat hepatic epidermal growth factor receptor: comparison of binding, immunodetection, and autophosphorylation. Toxicol Appl Pharmacol 1995: 132: 263272.
  • 176
    Bryant P L, Clark G C, Probst M R, Abbott B D. Effects of TCDD on Ah receptor, ARNT, EGF, and TGF-alpha expression in embryonic mouse urinary tract. Teratology 1997: 55: 326337.
  • 177
    Enan E, Matsumura F. Identification of c-Src as the integral component of the cytosolic Ah receptor complex, transducing the signal of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) through the protein phosphorylation pathway. Biochem Pharmacol 1996: 52: 15991612.
  • 178
    Cooper J A. Oncogenes and anti-oncogenes. Curr Opin Cell Biol 1990: 2: 285295.
  • 179
    Herschman H R. Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 1991: 60: 281319.
  • 180
    Dong L, Ma Q, Whitlock J P Jr. Down-regulation of major histocompatibility complex Q1b gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biol Chem 1997: 272: 2961429619.
  • 181
    Ishida S, Jinno H, Tanaka-Kagawa T et al. Characterization of human CYP1A1/1A2 induction by DNA microarray and alpha-naphthoflavone. Biochem Biophys Res Commun 2002: 296: 172177.
  • 182
    Prough R A. Introduction: basal and inducible expression of cytochromes P450 and related enzymes. FASEB J 1996: 10: 807808.
  • 183
    Nebert D W, Dalton T P, Okey A B, Gonzalez F J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004: 279: 2384723850.
  • 184
    Sutter T R, Guzman K, Dold K M, Greenlee W F. Targets for dioxin: genes for plasminogen activator inhibitor-2 and interleukin-1 beta. Science 1991: 254: 415418.
  • 185
    Gaido K W, Maness S C. Regulation of gene expression and acceleration of differentiation in human keratinocytes by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 1994: 127: 199208.
  • 186
    Choi E J, Toscano D G, Ryan J A, Riedel N, Toscano W A Jr. Dioxin induces transforming growth factor-alpha in human keratinocytes. J Biol Chem 1991: 266: 95919597.
  • 187
    Dohr O, Vogel C, Abel J. Modulation of growth factor expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Exp Clin Immunogenet 1994: 11: 142148.
  • 188
    Madhukar B V, Ebner K, Matsumura F, Bombick D W, Brewster D W, Kawamoto T. 2,3,7,8-Tetrachlorodibenzo-p-dioxin causes an increase in protein kinases associated with epidermal growth factor receptor in the hepatic plasma membrane. J Biochem Toxicol 1988: 3: 261277.
  • 189
    Couture L A, Abbott B D, Birnbaum L S. A critical review of the developmental toxicity and teratogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin: recent advances toward understanding the mechanism. Teratology 1990: 42: 619627.
  • 190
    Abbott B D, Birnbaum L S. TCDD alters medial epithelial cell differentiation during palatogenesis. Toxicol Appl Pharmacol 1989: 99: 276286.
  • 191
    Gaido K W, Maness S C, Leonard L S, Greenlee W F. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-dependent regulation of transforming growth factors-alpha and -beta 2 expression in a human keratinocyte cell line involves both transcriptional and post-transcriptional control. J Biol Chem 1992: 267: 2459124595.
  • 192
    Karyala S, Guo J, Sartor M et al. Different global gene expression profiles in benzo[a]pyrene- and dioxin-treated vascular smooth muscle cells of AHR-knockout and wild-type mice. Cardiovasc Toxicol 2004: 4: 4773.
  • 193
    Abbott B D, Birnbaum L S. TCDD-induced altered expression of growth factors may have a role in producing cleft palate and enhancing the incidence of clefts after coadministration of retinoic acid and TCDD. Toxicol Appl Pharmacol 1990: 106: 418432.
  • 194
    Barker C W, Fagan J B, Pasco D S. Interleukin-1 beta suppresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes. J Biol Chem 1992: 267: 80508055.
  • 195
    Gasiewicz T A, Neal R A. 2,3,7,8-Tetrachlorodibenzo-p-dioxin tissue distribution, excretion, and effects on clinical chemical parameters in guinea pigs. Toxicol Appl Pharmacol 1979: 51: 329339.
  • 196
    Brewster D W, Matsumura F. Differential effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on adipose tissue lipoprotein lipase activity in the guinea pig, rat, hamster, rabbit, and mink. Comp Biochem Physiol C 1989: 93: 4953.
  • 197
    Clark G C, Taylor M J, Tritscher A M, Lucier G W. Tumor necrosis factor involvement in 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated endotoxin hypersensitivity in C57BL/6J mice congenic at the Ah locus. Toxicol Appl Pharmacol 1991: 111: 422431.
  • 198
    Taylor M J, Lucier G W, Mahler J F, Thompson M, Lockhart A C, Clark G C. Inhibition of acute TCDD toxicity by treatment with anti-tumor necrosis factor antibody or dexamethasone. Toxicol Appl Pharmacol 1992: 117: 126132.
  • 199
    Kolluri S K, Weiss C, Koff A, Gottlicher M. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev 1999: 13: 17421753.
  • 200
    Matikainen T, Perez G I, Jurisicova A et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat Genet 2001: 28: 355360.
  • 201
    Zeytun A, McKallip R J, Fisher M, Camacho I, Nagarkatti M, Nagarkatti P S. Analysis of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced gene expression profile in vivo using pathway-specific cDNA arrays. Toxicology 2002: 178: 241260.
  • 202
    Hurst C H, Abbott B, Schmid J E, Birnbaum L S. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) disrupts early morphogenetic events that form the lower reproductive tract in female rat fetuses. Toxicol Sci 2002: 65: 8798.
  • 203
    Ohbayashi T, Oikawa K, Iwata R et al. Dioxin induces a novel nuclear factor, DIF-3, that is implicated in spermatogenesis. FEBS Lett 2001: 508: 341344.
  • 204
    Knutson J C, Poland A. Keratinization of mouse teratoma cell line XB produced by 2,3,7,8-tetrachlorodibenzo-p-dioxin: an in vitro model of toxicity. Cell 1980: 22: 2736.
  • 205
    Greenlee W F, Dold K M, Osborne R. Actions of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on human epidermal keratinocytes in culture. In Vitro Cell Dev Biol 1985: 21: 509512.
  • 206
    Hudson L G, Toscano W A Jr, Greenlee W F. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) modulates epidermal growth factor (EGF) binding to basal cells from a human keratinocyte cell line. Toxicol Appl Pharmacol 1986: 82: 481492.
  • 207
    Milstone L M, LaVigne J F. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces hyperplasia in confluent cultures of human keratinocytes. J Invest Dermatol 1984: 82: 532534.
  • 208
    Osborne R, Greenlee W F. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) enhances terminal differentiation of cultured human epidermal cells. Toxicol Appl Pharmacol 1985: 77: 434443.
  • 209
    Puhvel S M, Sakamoto M. Response of murine epidermal keratinocyte cultures to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): comparison of haired and hairless genotypes. Toxicol Appl Pharmacol 1987: 89: 2936.
  • 210
    Loertscher J A, Sattler C A, Allen-Hoffmann B L. 2,3,7,8-Tetrachlorodibenzo-p-dioxin alters the differentiation pattern of human keratinocytes in organotypic culture. Toxicol Appl Pharmacol 2001: 175: 121129.
  • 211
    Smola H, Thiekotter G, Fusenig N E. Mutual induction of growth factor gene expression by epidermal-dermal cell interaction. J Cell Biol 1993: 122: 417429.
  • 212
    Maas-Szabowski N, Szabowski A, Stark H J et al. Organotypic cocultures with genetically modified mouse fibroblasts as a tool to dissect molecular mechanisms regulating keratinocyte growth and differentiation. J Invest Dermatol 2001: 116: 816820.
  • 213
    Botchkarev V A, Kishimoto J. Molecular control of epithelial–mesenchymal interactions during hair follicle cycling. J Investig Dermatol Symp Proc 2003: 8: 4655.
  • 214
    Rendl M, Lewis L, Fuchs E. Molecular dissection of mesenchymal–epithelial interactions in the hair follicle. PLoS Biol 2005: 3: e331.
  • 215
    Sadek C M, Allen-Hoffmann B L. Cytochrome P450IA1 is rapidly induced in normal human keratinocytes in the absence of xenobiotics. J Biol Chem 1994: 269: 1606716074.
  • 216
    Poland A, Glover E. 2,3,7,8-Tetrachlorodibenzo-p-dioxin: segregation of toxicity with the Ah locus. Mol Pharmacol 1980: 17: 8694.
  • 217
    Vogel C F, Matsumura F. Interaction of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) with induced adipocyte differentiation in mouse embryonic fibroblasts (MEFs) involves tyrosine kinase c-Src. Biochem Pharmacol 2003: 66: 12311244.
  • 218
    Schiller C M, Adcock C M, Moore R A, Walden R. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and fasting on body weight and lipid parameters in rats. Toxicol Appl Pharmacol 1985: 81: 356361.
  • 219
    Pelclova D, Fenclova Z, Preiss J et al. Lipid metabolism and neuropsychological follow-up study of workers exposed to 2,3,7,8-tetrachlordibenzo-p-dioxin. Int Arch Occup Environ Health 2002: 75 (Suppl.): S60S66.
  • 220
    Loertscher J A, Lin T M, Peterson R E, Allen-Hoffmann B L. In utero exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin causes accelerated terminal differentiation in fetal mouse skin. Toxicol Sci 2002: 68: 465472.
  • 221
    Tauchi M, Hida A, Negishi T et al. Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions. Mol Cell Biol 2005: 25: 93609368.
  • 222
    Arnold I, Watt F M. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 2001: 11: 558568.
  • 223
    Waikel R L, Kawachi Y, Waikel P A, Wang X J, Roop D R. Deregulated expression of c-Myc depletes epidermal stem cells. Nat Genet 2001: 28: 165168.
  • 224
    Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W. beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 2001: 105: 533545.
  • 225
    Panteleyev A A, Thiel R, Rosenbach T, Christiano A M. Acne chlorina and acne vulgaris – casual likeness or casual homology? Arch Dermatol Res 2000: 292: 577581.
  • 226
    Cotsarelis G, Kaur P, Dhouailly D, Hengge U, Bickenbach J. Epithelial stem cells in the skin: definition, markers, localization and functions. Exp Dermatol 1999: 8: 8088.
  • 227
    Fuchs E. Beauty is skin deep: the fascinating biology of the epidermis and its appendages. Harvey Lect 1998: 94: 4777.
  • 228
    Taylor G, Lehrer M S, Jensen P J, Sun T T, Lavker R M. Involvement of follicular stem cells in forming not only the follicle but also the epidermis. Cell 2000: 102: 451461.
  • 229
    Panteleyev A A, Jahoda C A, Christiano A M. Hair follicle predetermination. J Cell Sci 2001: 114: 34193431.
  • 230
    Murante F G, Gasiewicz T A. Hemopoietic progenitor cells are sensitive targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J mice. Toxicol Sci 2000: 54: 374383.
  • 231
    Fine J S, Silverstone A E, Gasiewicz T A. Impairment of prothymocyte activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Immunol 1990: 144: 11691176.
  • 232
    Silverstone A E, Frazier D E Jr, Gasiewicz T A. Alternate immune system targets for TCDD: lymphocyte stem cells and extrathymic T-cell development. Exp Clin Immunogenet 1994: 11: 94101.
  • 233
    Knutson J C, Poland A. Response of murine epidermis to 2,3,7,8-tetrachlorodibenzo-p-dioxin: interaction of the ah and hr loci. Cell 1982: 30: 225234.
  • 234
    Gu Y Z, Hogenesch J B, Bradfield C A. The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 2000: 40: 519561.
  • 235
    Xu C, Li C Y, Kong A N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005: 28: 249268.
  • 236
    Hombach-Klonisch S, Pocar P, Kietz S, Klonisch T. Molecular actions of polyhalogenated arylhydrocarbons (PAHs) in female reproduction. Curr Med Chem 2005: 12: 599616.
  • 237
    Takagi S, Tojo H, Tomita S et al. Alteration of the 4-sphingenine scaffolds of ceramides in keratinocyte-specific Arnt-deficient mice affects skin barrier function. J Clin Invest 2003: 112: 13721382.
  • 238
    Tomita S, Jiang H B, Ueno T et al. T cell-specific disruption of arylhydrocarbon receptor nuclear translocator (Arnt) gene causes resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced thymic involution. J Immunol 2003: 171: 41134120.
  • 239
    Tomita S, Sinal C J, Yim S H, Gonzalez F J. Conditional disruption of the aryl hydrocarbon receptor nuclear translocator (Arnt) gene leads to loss of target gene induction by the aryl hydrocarbon receptor and hypoxia-inducible factor 1alpha. Mol Endocrinol 2000: 14: 16741681.
  • 240
    Jones C L, Reiners J J Jr. Differentiation status of cultured murine keratinocytes modulates induction of genes responsive to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Arch Biochem Biophys 1997: 347: 163173.
  • 241
    Jensen P J, Yang T, Yu D W et al. Serpins in the human hair follicle. J Invest Dermatol 2000: 114: 917922.
  • 242
    Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000: 19: 25482556.
  • 243
    Ray S S, Swanson H I. Alteration of keratinocyte differentiation and senescence by the tumor promoter dioxin. Toxicol Appl Pharmacol 2003: 192: 131145.
  • 244
    Murphy K A, Villano C M, Dorn R, White L A. Interaction between the aryl hydrocarbon receptor and retinoic acid pathways increases matrix metalloproteinase-1 expression in keratinocytes. J Biol Chem 2004: 279: 2528425293.
  • 245
    Mimeault M, Bonenfant D, Batra S K. New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers. Skin Pharmacol Physiol 2004: 17: 153166.
  • 246
    Oshima H, Rochat A, Kedzia C, Kobayashi K, Barrandon Y. Morphogenesis and renewal of hair follicles from adult multipotent stem cells. Cell 2001: 104: 233245.
  • 247
    Cotsarelis G, Sun T T, Lavker R M. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 1990: 61: 13291337.
  • 248
    Morris R J, Potten C S. Slowly cycling (label-retaining) epidermal cells behave like clonogenic stem cells in vitro. Cell Prolif 1994: 27: 279289.
  • 249
    Morris R J, Potten C S. Highly persistent label-retaining cells in the hair follicles of mice and their fate following induction of anagen. J Invest Dermatol 1999: 112: 470475.
  • 250
    Honeycutt K A, Roop D R. c-Myc and epidermal stem cell fate determination. J Dermatol 2004: 31: 368375.
  • 251
    Chen C R, Kang Y, Siegel P M, Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 2002: 110: 1932.
  • 252
    Pelengaris S, Khan M. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth. Expert Opin Ther Targets 2003: 7: 623642.
  • 253
    Schrenk D, Muller M, Merlino G, Thorgeirsson S S. Interactions of TCDD with signal transduction and neoplastic development in c-myc transgenic and TGF-alpha transgenic mice. Arch Toxicol Suppl 1997: 19: 367375.
  • 254
    Ashida H, Nagy S, Matsumura F. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-induced changes in activities of nuclear protein kinases and phosphatases affecting DNA binding activity of c-Myc and AP-1 in the livers of guinea pigs. Biochem Pharmacol 2000: 59: 741751.
  • 255
    Nagashima H, Matsumura F. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-induced down-regulation of glucose transporting activities in mouse 3T3-L1 preadipocyte. J Environ Sci Health B 2002: 37: 114.
  • 256
    Merrill B J, Gat U, DasGupta R, Fuchs E. Tcf3 and Lef1 regulate lineage differentiation of multipotent stem cells in skin. Genes Dev 2001: 15: 16881705.
  • 257
    Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 2001: 276: 60616064.
  • 258
    Morin P J. beta-Catenin signaling and cancer. Bioessays 1999: 21: 10211030.
  • 259
    Behrens J. Control of beta-catenin signaling in tumor development. Ann N Y Acad Sci 2000: 910: 2133.
  • 260
    Smalley M J, Dale T C. Wnt signaling and mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2001: 6: 3752.
  • 261
    Wang Y H, Li F, Schwartz J H, Flint P J, Borkan S C. c-Src and HSP72 interact in ATP-depleted renal epithelial cells. Am J Physiol Cell Physiol 2001: 281: C1667C1675.
  • 262
    Blanpain C, Lowry W E, Geoghegan A, Polak L, Fuchs E. Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 2004: 118: 635648.
  • 263
    Watt F M. Epidermal stem cells: markers, patterning and the control of stem cell fate. Philos Trans R Soc Lond B Biol Sci 1998: 353: 831837.
  • 264
    EPA US. Interim Report on Data and Methods for Assessment of 2,3,7,8-Tetrachlorodibenzo-p-dioxin Risk to Aquatic Life and Associated Wildlife. Duluth, MN: EPA US, March 1993: 1159.
  • 265
    Waikel R L, Kawachi Y, Waikel P A, Wang X J, Roop D R. Deregulated expression of c-Myc depletes epidermal stem cells. Nat Genet 2001: 28: 165168.